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The interaction between the IQ and ICDI domains in L-type Ca2+ channels is both 
functionally important and mechanistically intriguing. By preventing calmodulin from 
binding to the IQ domain, the ICDI domain diminishes channel open probability and 
Ca2+/CaM dependent inactivation (CDI). In this work, we performed alanine scanning of 
the entire IQ and ICDI domains. Hotspot mutations which reduce IQ/ICDI binding 
affinity also commensurately diminish ICDI function (i.e., permit restoration of CDI). 
The ensemble of effects can be well fit with a Langmuir equation. The collection of 
hotspots also allowed us to identify the segment downstream of the IQ contributing to the 
interaction. Further, we discovered a novel PKA phosphorylation site on the ICDI domain 
of CaV1.4, so PKA activation diminishes the IQ and ICDI interaction and thus increases 
channel open probability and CDI. As CaV1.4 is the major Ca2+ channels in the retina, 
this modulation might contribute to the circadian rhythms of visual sensitivity.  
On the other hand, FRET two-hybrid is an important tool for this work, which 
allows us to measure the binding affinities of protein interactions. Here we also extended 
the FRET assays to novel platforms, including flow cytometer and plate reader, in order 
to study protein interactions and identify small molecules interfering protein interactions 
in high throughput. We also developed a lysate-based FRET binding assay to calibrate the 
optical system and accurately measure binding affinities. Further, by applying weak 
helpers, we now can measure the binding affinities of weak protein interactions. 
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Voltage-gated Ca2+ channels (CaV channels) constitute prominent Ca2+ entry portals 
that affect a multitude of cell functions including muscle/neuron excitability, gene 
transcription, and downstream signaling pathways1-3. The CaV channel family is further 
divided into three major groups, CaV1, CaV2, and CaV3, based on sequence similarity (see 
the figure below). CaV1, the so called L-type calcium channel, has four members. CaV1.1 
mainly exists in skeletal muscle, and primarily acts as a voltage senor rather than an ion 
pore.  Because CaV1.1 channels conduct very small currents and are hard to study in 
heterologous systems, my thesis will focus on the other three L-type channels. CaV1.2 and 
1.3 are widely expressed, and coexist in many excitable cells. CaV1.2 is best known for 
initiating excitation-contraction (EC) coupling in ventricular myocytes, while CaV1.3 is 
more important for neuron function and sensory systems such as inner ear cells. Finally, 




                                                                         
 
 
   Family tree of CaV channels, adopted and modified from Ben-Johny et al4 
 





in order to tune the entry of calcium within each cell type. Calmodulin (CaM), a master 
regulator of ion channels, plays a central role in regulating CaV channels.   In a prototypical 
CaV channel, a single CaM is constitutively associated with the IQ domain of the channel 
carboxy terminus5, and enhances channel opening6. Moreover, Ca2+ binding to CaM 
triggers conformational changes that can decrease channel opening7, a process known as 
Ca2+/CaM dependent inactivation (CDI). However, long splice variants of CaV1.3 and 
CaV1.4 lack CDI due to a CDI inhibiting module (ICDI) that competes with CaM for 
binding to the IQ domain8. This lack of CDI is critical to maintaining light sensitivity in 
photoreceptors9,10 (CaV1.4) and sound sensitivity in inner hair cells11,12 (CaV1.3), both in 
response to prolonged stimuli. Indeed, mutations in the ICDI domain of these channels 
increase CDI, and lead to congenital stationary night blindness in patients13.  Beyond 
pathophysiology, the fact that ICDI can retune CDI-[apoCaM] relations points out the 
possibility that natural variations of Ca2+ free CaM (apoCaM) concentrations can modify 
CDI and Ca2+ entry, ultimately customizing cell function and Ca2+ homeostasis.  In this 
sense, ICDI may be considered as a master regulator of Ca2+ homeostasis, and as such, I 
will focus my thesis work on this very interesting module. 
 This thesis is composed of three parts. In the first part, extensive mutagenesis 
studies were performed to decode the interaction hotspots on the interface between IQ 
and ICDI. A unified mechanism was established for CaV1 channels, where by changing 
the ICDI binding affinity to the IQ domain, we can modulate the strength of this domain 





ICDI domain from CaV1.2 can regulate a special splice variant of CaV1.3, which might be 
a good example of trans-channel feedback regulation. 
As FRET two-hybrid is an established tool for probing protein interactions, the 
second part of this thesis is dedicated to designing novel platforms to improve and 
expand the capabilities of this assay. A lysate-based FRET assay allows accurate 
measurement of absolute binding affinities in a quasi-native context without purifying the 
proteins. Divalent binding with weak helpers can be used to measure binding affinities of 
weak protein interactions. Further, platforms such as plate readers and flow cytometers 
were deployed for FRET binding assays, allowing for the study of protein interactions in 
a higher throughput fashion. These assays were applied to study the IQ/ICDI interaction 
and potential modulators of this interaction. 
The third part of this thesis aims to identify specific regulators of the interaction 
between IQ and ICDI, which led to the discovery of a novel PKA phosphorylation site on 
the ICDI domain of CaV1.4. Phosphorylation of this site largely reduces the binding 
affinity between IQ and ICDI, and thus increases CDI and channel open probability.  
Overall, this thesis work provides significant insight into the molecular underpinnings of 













Chapter 1  
Resolving the grip of the distal carboxy tail on the 







Voltage-gated Ca2+ channels (CaV channels) constitute prominent Ca2+ entry portals that 
affect a multitude of cell functions including muscle/neuron excitability, gene 
transcription, and downstream signaling pathways1-3. As such, these channels are subject 
to rich and powerful modes of feedback regulation. For example, the ubiquitous Ca2+-
sensing molecule calmodulin (CaM) in the Ca2+-free form (apoCaM) is prebound to these 
channels at a carboxy-terminal IQ domain (Figure 1A)7,8,14. Upon elevation of 
intracellular Ca2+ concentration, this ‘resident’ CaM binds Ca2+ ions to drive 
conformational changes that ultimately inhibit channel opening. Displayed in Figure 1A, 
are recombinant CaV1.3 currents in HEK293 cells, evoked by a step depolarization to +10 
mV. With Ca2+ as the charge carrier, current decays quickly after activation, furnishing 
evidence of strong Ca2+-dependent inactivation (CDI). With Ba2+ as the charge carrier, 
however, there is little decline of current during the voltage pulse, as Ba2+ (which binds 
poorly to CaM) cannot initiate CDI. This CDI process is a crucial negative feedback 
mechanism that orchestrates Ca2+ homeostasis, protects against Ca2+ overload, and 
critically controls muscle/neuron excitabilit1,15-17. Thus far, what has been said about CDI 
pertains to nearly all CaV1-2 channels. This basic scheme of autoregulation is conserved 
across all high voltage-activated Ca2+ channels. Curiously, certain L-type Ca2+ channels 
(CaV1.3 and CaV1.4) also feature an alternatively spliced distal carboxy tail (DCT) that 
abolishes CDI. Mechanistically, a CDI-inhibiting module (ICDI, Figure 1B) on the DCT 
is thought to competitively inhibit apoCaM binding to the channel IQ domain and thereby 





these channels show only a small decrease in current, which is indicative of weak CDI. 
Importantly, recent studies also show that loss of apoCaM preassociation, as induced by 
the ICDI module, also sharply reduces the channel open probability6, adding to the 
richness of modulatory functions by the ICDI module.  
Despite these critical advances that outline the overall function of the ICDI 
module, the key structural elements that mediate the IQ/ICDI interaction remain largely 
undefined, with the exception of a single residue that mysteriously blunts ICDI effects8. 
Of note, the distal carboxy-terminus represents a large segment of the channel cytosolic 
domain thought to serve as a hub for numerous cellular signaling molecules. As such, in 
depth residue-level analysis will not only reveal potent interfaces to alter channel 
function, but may also facilitate the search for novel regulators of the family of IQ motif 
proteins.  
To characterize the landscape of the IQ/ICDI interaction of CaV1.3/1.4 channels, 
we undertook systematic alanine scanning mutagenesis of both IQ and ICDI domains. 
Through application of live-cell FRET two-hybrid binding assays, we identified several 
novel hotspots on both IQ and ICDI segments that mediate a high affinity interaction. 
Remarkably, functional analyses of these mutant channels demonstrated a weakened 
ICDI effect, resulting in restoration of CDI. A systematic analysis of such mutations 
revealed a strong inverse correlation (Figure 1C) between the strength of CDI and the 
binding affinity of the ICDI domain for the IQ segment as expected for a competitive 
inhibitor. Based on such extensive analysis, we built an ab initio computational structure 





competitive nature of ICDI and CaM interaction with the IQ domain. Finally, extending 
our analysis to CaV1.2 channels, we found that while the ICDI1.2 module binds poorly to 
the IQ domain of CaV1.2, it is, however, capable of regulating specific splice variants of 
CaV1.3 channels, revealing a novel trans-channel feedback regulation.  
 
Methods 
Molecular biology. The CaV1.3 channel (in pcDNA6) was derived from the rat 
brain variant (AF307009.1)20, and incorporated to the mammalian expression plasmid 
pCDNA6 (Invitrogen), which features a unique BglII restriction site at a locus 
corresponding to ~450 amino acids upstream of the IQ domain, and a unique XbaI site 
after the stop codon. The CaV1.2 (in pGW) is identical to rabbit NM00113652221, and 
CaV1.4 (in pCDNA3) is the human clone corresponding to NM007186. CaV1.3S/1.4DCT was 
made by fusing with the DCT of CaV1.4 to the CaV1.3 channel (truncated after the IQ 
domain), as previously described8. CaV1.343S was made by PCR amplification of the 
channel segment between the BglII site and IQ domain with the appendage of amino 
acids unique to this splice variant (Figure 6B). The PCR product was then inserted into 
the channel via the BglII/XbaI sites. 
FRET constructs were fluorescent-tagged (either Venus or Cerulean) using similar 
strategies as previously described14. Briefly, Venus and Cerulean fluorophores (a kind gift 
from Dr. Steven Vogel at NIH) were subcloned into the pcDNA3 vector via unique KpnI 
and NotI sites. The PCR-amplified channel peptides, as described in Liu et. al.8, were 





Mutations were introduced into the channel or FRET construct via PCR 
amplification or overlap extension PCR.  
Transfection of HEK293 cells. For electrophysiology experiments, HEK293 
cells were cultured on 10-cm plates, and channels were transiently transfected by a 
calcium phosphate protocol22. We applied 8 µg of plasmid DNA encoding the desired α1 
subunit, as well as 8 µg of β and 8 µg of rat α2δ (NM012919.2)23 subunits along with 3 
µg of SV40 T antigen.  
For microscope-based FRET assays, HEK293 cells cultured on 3.5-cm culture 
dishes with integral No. 0 glass coverslip bottoms (In Vitro Scientific) were transiently 
transfected using polyethylenimine (PEI) reagent (Polysciences).  
Whole-cell electrophysiology recording. Whole-cell recordings were obtained 
using an Axopatch 200A amplifier (Axon Instruments). Electrodes were pulled from 
borosilicate glass capillaries (Word Precision Instruments), with 1-3 MΩ resistances, 
which were in turn compensated for series resistance by >60%. Currents were low-pass 
filtered at 2 kHz before digital acquisition at five times the frequency. A P/8 leak-
subtraction protocol was used. The internal solution contained (in mM): CsMeSO3, 114; 
CsCl, 5; MgATP, 4; HEPES (pH 7.4), 10; and BAPTA (1,2-bis(o-aminophenoxy)ethane- 
N,N,N’,N’-tetraacetic acid), 10; at 295 mOsm adjusted with CsMeSO3. The bath solution 
was (in mM): TEA-MeSO3, 102; HEPES (pH 7.4), 10; CaCl2 or BaCl2, 40; at 305 mOsm 
adjusted with TEA-MeSO3. 
Microscope-based FRET optical imaging. FRET two-hybrid experiments were 





solution composed of (in mM): NaCl, 138; KCl, 4; MgCl2, 1; HEPES (pH 7.4), 10; 
CaCl2, 2; at 305mOsm adjusted with glucose. Background fluorescent signals were 
measured from cells without expression of the fluorophores, and subtracted from cells 
expressing the fluorophores. Concentration-dependent spurious FRET was subtracted 
from the raw data prior to binding-curve analysis7,14. Cerulean24 and Venus25 were used as 
the donor and acceptor fluorescent proteins instead of ECFP and EYFP, as their optical 
properties are better for this application. Acceptor-centric measurements of FRET were 
obtained with the 33-FRET algorithm7,14, which expresses the effective FRET efficiency 
(EEFF) and FRET ratio (FR) as: 
 𝐸𝐸EFF = 𝐸𝐸 × 𝐴𝐴b = (𝐹𝐹𝐹𝐹 − 1)[𝜀𝜀ven(440𝑛𝑛𝑛𝑛) 𝜀𝜀cer(440𝑛𝑛𝑛𝑛⁄ )]                      
where 𝐸𝐸 =  𝑘𝑘T/(𝑘𝑘T + 𝑘𝑘D) is the FRET efficiency of a donor-acceptor pair, 𝐴𝐴b is 
the fraction of acceptor molecules bound by a donor. 𝜀𝜀ven(440𝑛𝑛𝑛𝑛)/𝜀𝜀cer (440𝑛𝑛𝑛𝑛) is the 
approximate molar extinction coefficients of Cerulean and Venus, which was measured as 
0.08 on our setup.  
Molecular modelling. Ab initio structural prediction was performed using the 
Robetta online server26 (http://robetta.bakerlab.org), and web-based molecular docking 
programs Patchdock19 (http://bioinfo3d.cs.tau.ac.il/PatchDock/) was used to obtain 







Alanine Scanning Mutagenesis reveals high affinity anchors for ICDI segment 
To identify key residues that support a high-affinity IQ/ICDI interaction, we 
undertook systematic alanine substitution of the IQ domain and evaluated both the 
relative binding affinity and the strength of ICDI mediated inhibition of CaM regulation. 
Importantly, the ICDI domains of both CaV1.3 and CaV1.4 are highly homologous, and 
have been shown to interact with IQ domains in like manner evoking similar functional 
effects8. Even so, the ICDI1.4 has a very high binding affinity for IQ domains of both 
CaV1.3 and CaV1.4, with FRET binding assays yielding more robust measurements with 
better signal to noise ratio. Moreover, robust expression of the holo-CaV1.4 channel in 
recombinant systems is notoriously challenging. Accordingly, for simplicity, our 
structure-function analysis interrogates the interaction of ICDI1.4 with the CaV1.3 IQ 
domain, and further characterizes the functional consequences of this interaction using a 
chimeric CaV1.3 channel containing the distal carboxy-tail of CaV1.4. 
FRET binding pairs were constructed by tagging cerulean fluorescent protein to 
the ICDI domain from CaV1.4 and venus fluorescent protein to PreIQ3-IQ-A1.3, a peptide 
that includes ~ 50 residues both upstream (PreIQ3) and downstream (A-region) of CaV1.3 
IQ domain (Figure 1D). Both PreIQ3 and A regions were included initially for the 
purpose of facilitating peptide folding and expression. While strong binding was detected 
between the Venus-PreIQ3-IQ-A1.3 and Cerulean-ICDI1.4 ((Figure 1D), middle, green 
circles and green curve), there is little FRET interaction between a peptide containing the 





We began with systematic alanine scanning mutagenesis of the IQ domain of 
chimeric CaV1.3S/1.4DCT, where each residue in this region was mutated into an alanine or, 
at loci where the wild-type channel featured an alanine residue, a threonine. The FRET 2-
hybrid binding assay revealed that three residues, Y[-5]A, F[-2]A and F[+4]A, most 
severely perturbed the IQ/ICDI interaction (Figure 2A). Functional analysis of the F[-
2]A mutation revealed a partial rescue of CDI, suggesting weakened ICDI binding 
(Figure 2D). That said, other IQ domain substitutions Y[-5]A and F[+4]A resulted in 
minimal CDI rescue (Figure 2B). Importantly, these residues also serve as key anchors 
for apoCaM binding to the CaV1.3 IQ domain, resulting in weak baseline CDI even in the 
absence of the ICDI domain (Figure 2C)27. To account for this ambiguity, we consider a 
quantitative competitive inhibition model of CDI for CaV1.3S/1.4DCT channels 
incorporating both the IQ domain’s intrinsic affinity for apoCaM (Kd-Ch) and that for the 
ICDI segment (Kd-ICDI), the competitive inhibitor. Accordingly, CDI correlates inversely 
with binding affinity between IQ and ICDI (1 / Kd-ICDI), according to the relationship 











  (1) 
Here, CDI is the strength of CDI under endogenous levels of CaM; CDImax is the 
CDI in saturating concentrations of CaM; Kd-Ch is dissociation constant for apoCaM 
binding to holochannel in absence of ICDI; [apoCaM] is the free apoCaM concentration 
in cell; and [ICDI] is the effective local concentration of ICDI to IQ. Details about the 





correlation between 1 / Kd-ICDI and CDI. For channels contain intact IQ and ICDI 
domains, there is strong binding between the two (i.e. large 1 / Kd-ICDI) and minimal CDI, 
as shown by the green dot on Figure 1C and Figure 2E. By contrast, for channels 
without the ICDI domain, 1 / Kd-ICDI = 0 by definition, and thus CDI approaches CDImax, 
as shown by the light gray dot on Figure 1C and Figure 2E. As the IQ domain is critical 
for binding to both apoCaM and the ICDI segment, mutations in the IQ domain may then 
impact either Kd-Ch or Kd-ICDI. By contrast, mutations in the ICDI segment would simply 
impact Kd-ICDI. Figure 2E plots the ratio CDI / CDImax as a function of 1 / Kd-ICDI. For 
mutations like Y[-5]A or F[4]A, where Kd-Ch is altered, we compensate by multiplying Kd-
ICDI measured for these mutations (Figure 1A) by the ratio of Kd-Ch of mutated channels to 
Kd-Ch of the wild-type channel. This compensation works as long as the local 
concentration of ICDI is much greater than Kd-ICDI ([ICDI]>> Kd-ICDI).  Values for Kd-Ch 
were obtained from a previous study27 (Figure 2C). Once compensated, all relevant 
mutations follow the relation shown in Equation 1 well (Figure 2E). The parameters used 
in fitting Equation 1 are: [apoCaM] = 10µM, Kd-Ch = 0.05 µM, [ICDI] = 90 µM. 
Alanine scanning of ICDI region reveals complementary hotspots 
As binding can be perturbed by mutations in either binding partner, we continued 
to undertake alanine mutagenesis of the ICDI domain. Every three contiguous residues in 
the ICDI domain were substituted with alanines. The FRET two-hybrid binding assay 
revealed multiple novel hotspots on the ICDI segment with a wide range of affinities for 
the IQ domain.  Of note, the effects of the hotspots on the ICDI segment were 





axis in Figure 3A is much bigger than Figure 2A). Functional analysis of these mutants 
revealed restoration of CDI corresponding to the weakened IQ/ICDI interaction (Figure 
3B). For example, IAD[1914]AAA moderately reduced IQ/ICDI binding and thus 
partially restored CDI (Figure 3C); SLV[1886]AAA disrupted IQ/ICDI binding to a large 
extent, and correspondingly restored functional CDI (Figure 3D) to the level of CaV1.3S 
channels which lack ICDI (Figure 1C). All the newly identified hotspots fit well with 
Equation 1, using the same set of parameters as the IQ mutations (Figure 3E). The small 
amount of variability observed may be attributed to cell-to-cell variation in endogenous 
apoCaM concentrations.  Overall, the strong correlation of the IQ and ICDI data 
furnishes strong evidence for a competitive mechanism of ICDI action.   
The role of the A region in the IQ/ICDI interaction 
Curiously, even though our analysis identified several IQ domain hotspots, the 
impact of such mutations were far milder than that of ICDI hotspots (Figure 2 versus 
Figure 3). This suggested that regions upstream or downstream of IQ may also contribute 
to ICDI binding. To test this hypothesis, we constructed various truncations of Venus-
PreIQ3-IQ-A1.3, and paired them with Cerulean-ICDI1.4 in the FRET two-hybrid binding 
assays (Figure 4A). Truncations of the PreIQ3 region did not significantly alter ICDI 
binding (Figure 4B). However, truncation of the A region resulted in a sharply 
diminished ICDI interaction (Figure 4B), suggesting that this segment is critical despite 
the fact that the A-region alone did no support detectable ICDI binding (Figure 2A, open 
black circle). Serial truncations within the A region show that truncating up to the 35th 





additional truncations into the A region results in sharply reduced binding (Figure 4B, 
C). Thus, the 34 residues immediately downstream of the IQ domain critically augment 
ICDI binding. Accordingly, we conducted systematic alanine scanning mutagenesis of 
this critical segment of the A region, and found several novel hotspots for a high affinity 
IQ/ICDI interaction (Figure 4D). 
 Ab initio structure modeling by Rosetta. 
With functionally relevant hotspots for the IQ/ICDI interaction firmly identified, 
we constructed an ab initio molecular model to further scrutinize its role in competing 
with CaM.  While the atomic structure of the IQ domain of CaV channels is known 
(Figure 5A), no homologous structure of the ICDI domain can currently be found in the 
Protein Data Bank (PDB). Thus, we performed ab initio protein structure prediction on 
the ICDI segment using the Rosetta18. Next, we docked the structural model of the ICDI 
domain onto the IQ domain using Patchdock19, an online server for fast protein-protein 
docking based on shape complementarity. Among the ten highest-scoring output models 
from Patchdock, two corresponded well with our alanine scanning data as shown in 
Figure 5C and D. Notably, residue F[4] on the IQ domain (Figure 5D) forms a likely 
hydrophobic anchor with close proximity to residues V[1888] (in SLV) and I[1893] (in 
LIS) and V[1907] (in V) and M[1925] (in DEM), all hotspots identified in our alanine 
scanning mutagenesis experiments (Figure 3A, B). Importantly, F[4] is also a key the 
apoCaM contact on IQ region (Figure 3C and Figure 5A).  
Comparing models of apoCaM/IQ and IQ/ICDI interactions, we can see that 





F[4]) on one face of the IQ helix (Figure 5B), while ICDI wraps around the IQ domain 
from a slightly different angle compared to apoCaM. However, the bulky ICDI residing 
on the IQ can sterically repel apoCaM binding (Figure 5C), resulting in competitive 
inhibition at the molecular level. 
Exploring similar interactions within CaV1.2 
Similar to CaV1.3 and CaV1.4 channels, CaV1.2 channels also feature a 
homologous ICDI segment, argued to function as a channel inhibitor28,29  or as a 
transcriptional factor30,31. That said whether such putative roles relate to interaction of 
ICDI1.2 with the channel IQ domain is largely unknown. As such, we measured the 
binding affinity between Venus-PreIQ3-IQ-A1.2 and Cerulean-ICDI1.2 by FRET two-
hybrid assays and found that this interaction is ~10-fold weaker (Figure 7A) than the 
prototypic Venus-PreIQ3-IQ-A1.3 and Cerulean-ICDI1.4 interaction (Figure 1D). 
Importantly, we recently found a phosphorylation site on ICDI1.4, which reduces its 
binding affinity to the IQ region of CaV1.3/1.4 by about 10-fold and largely increases the 
CDI in chimeric CaV1.3S/1.4DCT and CaV1.4 channels (orange point in Figure 3C, see 
more in Chapter 3). This result indicates that the strength of ICDI1.2 in regulating 
calmodulation of the channel is substantially lower than that of the CaV1.3 and 1.4 
counterparts. Indeed, no obvious difference in CDI was observed between CaV1.2 with8 
or without the DCT32 by whole-cell electrophysiology. As such, we conclude that the 
interaction between the IQ and ICDI regions of CaV1.2 channels has a relatively low 





Interestingly, we found that ICDI1.2 has a higher affinity for IQ-A1.3 than IQ-A1.2 
(Figure 7A). Several recent studies have shown that the ICDI1.2 segment exist in neurons 
and cardiomyocytes as a peptide due to proteolysis28,33, or as a result of alternative 
transcriptional initiation sites30. We thus wondered if these peptides could interact with 
and regulate CaV1.3 channels. The canonical CaV1.3 channels exist in two forms, a long 
splice variant with the ICDI domain intact and thus exhibiting diminutive CDI and PO, 
and a short splice variant truncated shortly after the IQ domain and thus possessing large 
CDI and PO6,8. The long splice variant contains its own ICDI segment and is therefore 
unlikely to be further affected by the ICDI1.2 peptide. The canonical short splice variant 
(CaV1.342) contains only 10 residues in the A region, and is therefore not affected by the 
potent ICDI1.4 peptides (data not shown). A recently discovered splice variant CaV1.343S, 
on the other hand, has a premature stop codon after the first one third of the A region34. It 
thus contains the minimal IQ-A domain necessary for ICDI binding. While these 
channels exhibit strong CDI when expressed alone, they display minimal CDI when 
coexpressed with the potent ICDI1.4 peptides (Figure 7B, C). Interestingly, they also 
exhibit largely diminished CDI when coexpressed with the ICDI1.2 peptide (Figure 7B, 
C).  The CDI and FRET binding data measured for CaV1.343S coexpressed with ICDI1.2 
reside on a Langmuir curve (Figure 7D) which is slightly right-shifted from the previous 
one described in Figure 2 and Figure 3, reflecting the reduced effective local 
concentration of ICDI near the IQ domain, as the ICDI segment is no longer fused to the 





described regulatory functions29,30,30, the ICDI1.2 peptide may also regulate the closely 
related CaV1.3 channels, establishing a novel mode of trans-channel regulation. 
 
Discussion  
Calmodulation of CaV channels is a central prototype for high-order Ca2+ 
decoding. Beyond its role as a master regulator of ion channels, CaM is a key signaling 
molecule capable of binding a wide range of molecules. In addition to CaV channels, a 
number of proteins, such as neuromodulin and neurogranin, contain IQ-motifs that 
interact with CaM. The family of IQ-motif containing proteins have little sequence 
similarity outside of the IQ-domain, allowing for diverse functionality. Mechanistically, 
ICDI plays a unique role as a regulator of the CaV IQ domain. Are there other proteins 
that utilize a similar strategy to regulate CaM signaling? Understanding the structural 
details of IQ/ICDI interaction and decoding key motifs within the ICDI would facilitate 
the search for regulators of varied IQ-motif proteins.  
More broadly, the distal carboxy tail (DCT) could be a key module for 
understanding the functional diversity of CaV channels, especially those with similar 
biophysical and pharmacological properties, as determined by highly conserved pore and 
proximal carboxy-tail regions. Compared to these regions, the DCT (which resides 
beyond these aforementioned regions of conservation) promises greater channel subtype 
selectivity due to greater sequence variability. Higher-order regulation of the DCT, such 
as phosphorylation (Chapter 3) and interaction with other proteins (Figure 6), also exists 





diversity of channel functions. Thus, understanding the functional diversity of the DCT 
provides novel opportunities for identifying small-molecule and synthetic peptide 
regulators targeted to specific channel subtypes. 
While X-ray crystallography offers high resolution atomic structures, the size of 
the channel makes protein crystallography prohibitive. Moreover, crystallization of even 
short channel segments have been challenging and the relevance of such structures to 
holochannel function is often controversial35,36. Here, we adopt an alternative approach, 
applying systematic alanine scanning of the IQ and ICDI domains to identify hotspots of 
the IQ and ICDI interaction.  Moreover, we have utilized the resulting information to aid 
in building a structural model through ab initio computational protein structure prediction 
and docking. The detailed map of the IQ/ICDI interaction also helps us to understand the 
role played by another important region, the A region. Unlike the IQ domain, the A region 
is not directly involved in calmodulation, but it is likely that the A region forms an 
interface with ICDI and contributes to its binding to the IQ domain, and regulation of 
calmodulation of these channels. 
The quantitative FRET two-hybrid live cell binding and patch clamping assays 
allow us to fit data of all mutations studied to a Langmuir equation, furnishing strong 
evidence of a competitive inhibitor model8. While we postulate a unified mechanism of 
ICDI modulation across CaV1 channel families, the DCT of CaV2 channels are much less 
homologous to CaV1 channels and do not bind to IQ regions (data not show). Early 
studies show that the DCT of these channels, particularly CaV2.1, can modulate 





Several studies have explored the role of the DCT in CaV1.2. Hulme et al. found 
that CaV1.2 channels in cardiac muscle and brain and CaV1.1 channels in skeletal muscle 
undergo proteolytic cleavage28,33. They then applied mass spectroscopy to identify the 
proteolytic cleavage site in CaV1.1 and argued for a similar proteolytic site in CaV1.2 
(Ala1800, red arrow, Figure 6). They further showed that the cleaved DCTs of CaV1.2 
channels can re-associate with the truncated channel backbone and inhibit channel 
activity28,29. The underlying molecular mechanism of channel inhibition is the interaction 
between the proximal C-terminal regulator domain (PCRD) on the truncated channel and 
the distal C-terminal regulator domain (DCRD) on the cleaved DCT28,29. The inhibitory 
function of the DCT from CaV1.2 seems to be consistent with observations by Adams et 
al in CaV1.3/1.4. Furthermore, PCRD is homologous to the beginning of the A region in 
CaV1.3/1.4 which contributes to the IQ/ICDI interaction, and DCRD is homologous to 
part of the ICDI region in CaV1.3/1.4 (Figure 6). Thus, it is likely that the PCRD/DCRD 
interaction is part of the interaction between the IQ-A and ICDI regions. Our study argues 
that this interaction is likely relatively weak in CaV1.2 channels. However, it is interesting 
to see that the trans-channel interaction between IQ and ICDI is much stronger, implying 
that ICDI1.2 peptides may regulate some CaV1.3 splice variants. Given the evidence that 
DCT peptides of CaV1.2 exist due to proteolysis28,33 or alternative promoters30, they may 
regulate CaV1.3 channels, resulting in  significant biological effects in neurons and 
































Figure 1. ICDI element weakens Ca2+ regulation of the channels by a competitive 
mechanism.  
(A) Short splice variant of CaV1.3 channels (CaV1.3S) exhibit strong CDI. (left) IQ element 
(circle, on intracellular carboxy terminus) prebinds apoCaM (green dumbbell). (right) Ba2+ 
(black trace) and Ca2+ (red trace) currents evoked by depolarization to +10 mV.  Strong 
Ca2+ current decay in comparison to Ba2+ current during depolarization indicates strong 
CDI. The vertical scale bar applies to Ca2+ here and throughout. Ba2+ currents scaled 2-3× 
downward to facilitate visual comparison of decay kinetics. (B) Chimeric CaV1.3S/1.4DCT 
channels with an ICDI element (red rectangle) exhibit little CDI. (C) An inverse correlation 
between measured CDI and the binding affinity of the IQ/ICDI interaction (1 / Kd-ICDI). (D) 
FRET two-hybrid assay of IQ/ICDI interaction. FRET partners are Venus-PreIQ3-IQ-A1.3 
and Cerulean-ICDI1.4 peptides (left cartoon). Strong binding-curve (left, green curve) of 
wild-type FRET partners detected by live-cell FRET (green circles, each from single 
HEK293 cell expressing FRET partners). No FRET interaction between the A region alone 


































Figure 2. Systematic alanine scanning of the IQ region.  
(A) FRET two-hybrid assay of IQ/ICDI interaction. FRET partners are Venus-PreIQ3-IQ-
A1.3 and Cerulean-ICDI1.4 peptides (left cartoon). Alanine was systematically substituted 
into the IQ region of Venus-PreIQ3-IQ-A1.3 (left cartoon, star), and repeated FRET two-
hybrid assays were performed with Cerulean-ICDI1.4 peptides. Kd-ICDI measured for all 
constructs (right) unveiled several hotspots for IQ/ICDI binding. The green dotted line 
indicates the Kd-ICDI measured for the wild-type binding partners. (B) CDI analysis of 
hotspots with the most severe impact on Kd-ICDI, using channels as diagrammed on the left. 
The green dotted line indicates CDI measured for the channel in Figure 1B.  (C) 1 / Kd-Ch , 
binding affinity of apoCaM to holochannel in the absence of ICDI, measured directly by 
FRET two-hybrid assay or derived from CDI measurements using whole-cell patch clamp 
described in a previous study27. The green dotted line indicates the Kd-Ch measured for the 
wild-type binding partners.  (D) F[-2]A illustrates decreased binding affinity (upper, blue 
curve), and exhibits increased CDI over wild-type chimeric channels (Figure 1B). (E) 
After adjustment for the alterations in 1 / Kd-Ch produced by alanine substitutions at these 
hotspots (C), CDI and binding data for these hotspot mutations (blue circles) fit well to the 
competitive-binding relation (black curve; Equation 1). The green circle is from CDI of the 
wild-type chimeric channels (Figure 1B) and corresponding FRET results (Figure 1D). 
The light gray circle corresponds to CDI of the CaV1.3S channel (Figure 1A); by definition, 

































Figure 3. Systematic alanine scanning of ICDI region.  
(A) FRET two-hybrid binding effects of systematic substitutions of alanine into the ICDI 
region of Cerulean-ICDI1.4 peptides (left, star), with Venus-PreIQ3-IQ-A1.3 as the FRET 
partner. Kd-ICDI landscape of the ICDI region unveiled multiple hotspots for IQ/ICDI 
interaction (left and right). The green dotted line indicates the Kd-ICDI measured for the 
wild-type binding partners. (B) CDI measured for the chimeric CaV1.3S/1.4DCT channels 
with mutations in ICDI hotspots. The light gray and green dotted line indicates CDI 
measured for the channels in Figure 1A and B respectively. (C) IAD[1914]AAA 
moderately reduced IQ/ICDI binding (upper) and thus partially restored CDI (lower). (D) 
SLV[1886]AAA disrupted IQ/ICDI binding to a large extent (upper) and correspondingly 
restored functional CDI (lower) to the level of CaV1.3S that lacks ICDI (Figure 1C). (E) 
Robust fit of CDI (B) and FRET binding data (A) (red symbols) to a competitive-binding 
relation (black curve, copied from Figure 2E as well as the light gray and green 
symbols). PKA phosphorylation at Ser1883 reduces the IQ/ICDI interaction and CDI 

























Figure 4. Exploring the role of the A region in the IQ/ICDI interaction. 
 (A) FRET interaction between Cerulean-ICDI1.4 and various truncations of Venus-PreIQ3-
IQ-A1.3. Blue box shows the sequence of the A region, with positions of residues in the A 
region marked underneath (boundary of A region in the channel is marked above the 
sequence, corresponding to Figure 6). (B, C) Truncating the PreIQ3 region barely affected 
1 / Kd-ICDI (B, light blue; C), whereas the IQ region alone supported far weaker binding (B, 
dark blue; C). A series of truncations within the A region (IQ-A∆1.3, the number below the 
bar indicates the length of the remaining A region after truncation) suggest that the first 34 
residues of the A region are critical for binding (B, C).  (D) FRET two-hybrid binding 
effects of systematic substitutions of alanine into the critical A region of Venus-PreIQ3-IQ-
A1.3 peptides (A, star), with Cerulean-ICDI1.4 as FRET partner. Kd-ICDI landscape of the 















Figure 5. Ab initio modeling of IQ/ICDI interaction, compared with IQ/apoCaM 
interaction.  
(A) F[4] (red sticks), the most significant hotspot of the IQ region (blue ribbon) for ICDI 
binding (Figure 2A), is also a hotspot for apoCaM binding (F[4] as well as I[0] and A[-4] 
in blue sticks). (B) Homology model of IQ domain complexed with the C-lobe of apoCaM 
(green ribbon and surface, based on NMR structure of analogous NaV1.5 complex39. (C) 
Ab initio (Rosetta) structural model of ICDI (red ribbon and surface) complexed with IQ. 









Figure 6. Detailed sequence information of the DCTs from L-type Ca2+ channels.  
Amino-acid alignments of the A, B, and ICDI regions from CaV1.2 (rabbit 
NM001136522.1), CaV1.3 (rat AF370009.1) and CaV1.4 (human NP005174). Dashed lines 
indicate gaps of alignment; dotted lines are omitted sequences. Coordinates of boundaries 
are annotated on the left of each sequence. Consensus symbols under the sequences 
indicate fully conserved residues (*), strongly similar residues (:) or weakly similar 
residues in each position. The light-red-shaded regions in the A region and ICDI region are 
PCRD and DCRD28 regions respectively. The previously identified proteolytic cleavage 
site in CaV1.233 is indicated by a red arrow.. The light-blue-shaded regions are segments 



























Figure 7. The ICDI1.2  peptide binds and regulates CaV1.343S.  
(A) FRET two-hybrid assay of IQ/ICDI interaction. FRET partners are Venus-PreIQ3-IQ-
A1.3 or Venus-PreIQ3-IQ-A1.2 peptide and Cerulean-ICDI1.2 peptide (left cartoon). Venus-
PreIQ3-IQ-A1.3 has higher affinity to Cerulean-ICDI1.2 (right) than Venus-PreIQ3-IQ-A1.2 
(middle). The gray curves are from a binding assay between Venus-PreIQ3-IQ-A1.2 and 
ceruealn-ICDI1.4. (B) (left) Cartoon of CaV1.343S, underneath the cartoon is its sequence 
after IQ, which is different from CaV1.342, another short splice variant truncated right 
after IQ. (right) Current exemplars show that CaV1.343S by itself has full born CDI, and 
coexpressing ICDI1.2 or ICDI1.4 can reduce its CDI. (C) Bar graphs of CDI show the same 
result as B. (D) CDI and FRET binding data measured for CaV1.343S coexpressed with 
ICDI1.2 peptide resides on a Langmuir curve (black) right-shifted from the one used in 
Figure 2 and Figure 3. The black curve was fitted using [ICDI] = 30 µM instead of 90 





















The live-cell FRET two-hybrid binding assay is a well-established and robust 
method for probing protein interactions. Unlike in-vitro methods, binding partners of 
interest are expressed and measured in their native environment. Thus, FRET two-hybrid 
suffers from a much lower false positive rate7 and is more likely to identify or confirm 
interactions with functional significance. Further, it is a quantitative method, allowing for 
measurement of relative binding affinities quantitatively correlated with function8,27,40.  
As such, this method has been used for a number of mechanistic discoveries7,8,14,27,40-42. 
Moreover, as there is no need to deal with solubility and other purification issues required 
of in-vitro methods, FRET two-hybrid is not only much easier to perform, but also 
provides a unique opportunity to study large membrane proteins such as voltage-gated 
calcium channels7. Recently, Ben-Johny et al. also demonstrated that FRET two-hybrid 
can be used to understand the stoichiometry of protein interactions43. 
However, this method also has its own limitations. First of all, because of the 
complexity of the optical pathways involved, FRET two-hybrid cannot not be used to 
obtain the absolute value of binding affinities in molar units. While calibration methods 
exist to convert the relative binding affinities to absolute values, it is hard to estimate the 
accuracy of these calibrations. On the other hand, while this method has a very low false 
positive rate, it suffers from a substantial false negative rate for two reasons: (1) in large 
protein complexes, fluorophores might exceed the Förster distance or may not reside in 
the ideal orientation, resulting in no FRET signal despite protein binding. This issue 





or fluorophore linkers44, changing the fluorophore tagging locations, and employing 
circularly permutated fluorophores45; however, these methods are usually very time 
consuming and are not guaranteed to work.  (2) FRET two-hybrid binding assays only 
work well when the dissociation constant is in the range of tens of nanomolars to a few 
micromolars. Low affinity binding interactions, which might have a functional 
significance when proteins colocalize in a native environment, may not be detected by 
FRET two-hybrid assays which usually use peptide segments homogeneously distributed 
in the cytosol. Lastly, the current platform for FRET two-hybrid assays are widefield and 
confocal microscope setups7,14,46, which do not scale well for high-throughput 
applications such as screening for small molecules capable of disrupting protein 
interactions or screening for binding partners of a protein of interest.  
To solve these issues, we designed novel platforms with which to perform FRET 
binding assays. First, we developed a lysate-based FRET assay to accurately measure 
binding affinities (in molar units) in a quasi-native context without protein purification. 
Second, we applied divalent binding with weak helpers to measure the binding affinity of 
weak protein interactions. Lastly, we extended the platform for FRET binding assays to 




Molecular biology. The four plasmids used for making lentivirus (LV) were 





Universtiy, Baltimore, MD47, including: (1) pRRLsin18.cPPT.CMV.eGFP.Wpre (named 
as pPPT-eGFP) , (2) pMDLg/pRRE, (3) pRSV-Rev,  (4) pMD2.VSV.G.  The cDNAs of 
Venus-PreIQ3-IQ-A1.3 and Cerulean-ICDI1.4 were cloned into pPPT-eGFP following the 
removal of eGFP. The resulting plasmids pPPT-Venus-PreIQ3-IQ-A1.3 and pPPT-
Cerulean-ICDI1.4 were combined with plasmids (2)-(4) respectively for transfection to 
generate LV-Venus-PreIQ3-IQ-A and LV-Cerulean-ICDI.  
Production of lentivirus. Lentivirus was produced by PEI transfection of the four 
lentivirus plasmids into HEK 293T cells. The supernatant from 293T cells was collected 
48 and 72 hours after transfection, filtered by 150ml Stericup (Millipore, SCHVU01RE) 
and concentrated using sterilized Centricon Plus-70 (Millipore, UFC710008) filters. The 
concentrated virus was stored at –80oC after calculating the titer by a serial dilution assay 
47,48. 
Making stable cell lines using lentivirus. 5-10ul of each concentrated virus (LV-
Venus-PreIQ3-IQ-A1.3 and LV-Cerulean-ICDI1.4) were thawed quickly at room 
temperature and added directly to HEK293 cells. 99% of cells were infected by the virus 
transduction. Several rounds of infection were used to achieve the desired expression 
level of virus, i.e., the plateau phase of the binding curve (Figure 13A). Then the cells 
were well separated and plated on 100mm cell culture dishes (BD, 353003) at the density 
of approximately 1000 cells/ml, allowing the formation of single colonies. After 7-10 
days in culture, single colonies were selected for proliferation and the colonies with the 
most homogeneous expression of the fluorophores were selected and expanded as stable 





RD), stable cell lines expressing only Venus-PreIQ3-IQ-A1.3 or Cerulean-ICDI1.4 were also 
made. 
Making stable cell lines using resistance selection. HEK293 cells were 
transfected with Cerulean-Venus dimer in C1 plasmid 49 and grown in complete DMEM 
media containing 400 µg/ml G418 for 10 days. Cells that survived the G418 selection 
were then split and plated on 100mm cell culture dishes (BD, 353003) at a density of 
approximately 1000 cells/ml in order to form single colonies. After 7-10 days in culture, 
single colonies were selected for proliferation and the colonies with the most 
homogeneous expression of the fluorophores were selected and expanded as stable cell 
lines. 
Cell culture. For microscope-based FRET optical imaging, HEK293 cells were 
plated at low density into 3.5 cm culture dishes with integral No. 0 glass cover slip 
bottoms (MatTek, P35G-0-14-C) and cultured for 1-3 days in complete DMEM media, 
i.e. DMEM media (Mediatech, 10-013-CV) supplemented with 10% Fetal Bovine Serum 
(Hyclone, SH30071.03), 2 mM L-Glutamine (Gibco, 25030), 50 IU/ml Penicillin, 50 
µg/ml Streptomycin (Mediatech, 20-001-CI), 10 µg/ml Gentamicin (Quality Biology, 
120-098-66IEA). 
For plate-reader-based FRET optical imaging, cells were resuspended in complete 
DMEM at the density of 400,000 cells/ml and loaded into BD Biocoat 384-well plates 
(BD, 354663) at 50 µl per well and incubated for 24 hours at 37 °C and 5% CO2. As 
shown in Figure 14A, columns 1-2 of the 384-well plate were plated with control cells 





rows M-P of columns 1-2 were plated with the stable cell line used for screening, without 
the addition of drug, as negative control. Columns 3-22 were plated with the stable cell 
line used for screening the Library of Pharmacologically Active Compounds (LOPAC, 
Sigma-Aldrich). Columns 23-24 were plated with the stable cell line used for screening 
(rows A-H) and another stable cell line with less CaM expression (rows I-P); ionomycin 
was added to cells cultured in these two columns as a positive control. 
Transient transfection. cDNAs of Venus-PreIQ3-IQ-A and Cerulean-ICDI (wild 
type or mutant) were cloned into pcDNA3 plasmids and transiently transfected by PEI 
(Polysciences, 23966-2) into HEK293 cells, which then were incubated at 37 °C in 5% 
CO2 for 1-2 days.  
Microscope-based FRET optical imaging. Cells were washed, bathed in 
HEPES-buffered Tyrode’s solution (pH 7.35) containing 10mM Ca2+, and assayed with a 
Nikon TE300 Eclipse microscope (40× 1.3 n.a. oil objective) and custom fluorometer 
system (University of Pennsylvania Biomedical Instrumentation Group). Each individual 
cell was picked by an image-plane pinhole, and epifluorescence emission from the entire 
cell was measured by the three-cube FRET method14; 30-50 individual cells were 
measured and analyzed as described previously14, to generate a binding curve. 
Plate-reader-based FRET optical imaging. Cells were washed, bathed in 
Tyrode’s solution containing 10 mM Ca2+. As shown in Figure 14A, compounds from 
the LOPAC or Molecular Libraries Small Molecule Repository (MLSMR, Evotec Inc.) 
libraries were added to columns 3-22 at 25 µM, and ionomycin was added to columns 23-





µM. Cells were incubated at room temperature for 10 min after adding the library 
compounds and then mounted on a Safire2 plate reader (Tecan) or Perkin Elmer 2102 
Envision, measured and analyzed by a three-cube FRET method as described previously 
with modifications14.  
Flow-cytometer-based FRET optical imaging. FRET two-hybrid experiments 
were performed on an Attune Acoustic Focusing Cytometer (Life Technologies) as 
described49. Cells were trypsinized and resuspended in Tyrode’s solution before loading 
onto the flow cytometer. The previously described algorithm 7,14 was used to calculate 
acceptor-centric measures. In total, signals from 1,000-10,000 cells were recorded and 
analyzed by home-made software written in MATLAB.  
Cell lysate preparation.  Cells were trypsinized and washed twice in HEPES-
buffered Tyrode’s solution (pH 7.35) containing 2mM Ca2+, and precipitated by 
centrifugation and weighed. Physiological lysis solution (100µl lysis solution per 100mg 
wet weight of the cell pellet) was added and cells were lysed by one cycle of freezing and 
thawing. The insoluble fraction was removed by centrifugation.   
The physiological lysis solution contained (in mM): KCl: 20; K-gluconate: 120; 
MgCl2: 2; EGTA: 0.2; HEPES: 10 (pH 7.4); Na2-ATP: 2; DTT: 10; EDTA-free protease 
inhibitor cocktail (Roche): following instruction; at 305 mOsm adjusted by K-gluconate. 
Absorption and excitation spectrum measured for cell lysate. Absorption 
spectra were measured by UV-Vis spectrophotometer (Beckman) with an ultra micro 
quartz cuvette (0.05mL, z = 8.5mm). Excitation spectra were measured by fluorolog 





Lysate-based FRET optical imaging. 10-20ul of cell lysates were loaded on No. 
0 glass cover slip bottom (MatTek, P35G-0-14-C) and quickly measured (before 
evaporation) on a Nikon TE300 Eclipse microscope (40× 1.3 n.a. oil objective) and 
custom fluorometer system (University of Pennsylvania Biomedical Instrumentation 
Group). The lysate droplet was large enough to cover the whole field picked by an image-
plane pinhole. However, the droplet had depth and a number of focal planes. To be 
consistent, the readings were obtained at the maximal output of the PMT. 
Epifluorescence emission was measured and analyzed by the three-cube FRET method14. 
To obtain lysates with lower concentrations of the fluorescent protein, lysates from cells 
with fluorescent protein expressed were diluted 1:1 using lysates from cell without 
fluorescent protein expression. Even though we carefully adjusted the amount of lysis 
solution when preparing cell lysate, there was still variability in the cell and lysate 
concentration from trial-to-trial. Thus, lysis solution was added to each lysate such that 
the absorbance was adjusted to 0.3 AU at 670nm before any measurements and dilutions. 
Ionomycin effect. Ionomycin (Sigma-Aldrich, I0634) was dissolved in 99.5% 
DMSO (Sigma-Aldrich, D5879) to form a 10mM stock, and diluted by a Tyrode’s 
solution containing 10mM Ca2+ to a final concentration of 10µM. Cells were incubated in 







Lysate-based FRET assay to measure binding affinity 
The basic idea of the lysate-based FRET assay is to use the absorption spectrum 
to accurately measure the concentration of fluorescent proteins, and calibrate the relative 
binding affinities measured by FRET binding assays to absolute values in molar units. 
First, we obtained absorption spectra of lysates from cells without expression of any 
fluorescent proteins (background lysate). As illustrated in Figure 8A and B, background 
lysates could have high absorption, especially at short wavelengths (Figure 8A, B, gray 
traces), which is caused by endogenous proteins, nucleotides and autofluorescent 
materials such as NADPH and flavins. Even though the absolute value of the absorption 
spectrum at a certain wavelength varies from one experiment to another due to variability 
in preparing lysates (see cell lysate preparation in Methods), the overall shape of the 
spectra are always the same, and can overlap well if scale by a constant value. Next, we 
measured the absorbance of lysates from cells expressing the Venus-PreIQ3-IQ-A1.3 
peptide (Venus lysate). Its absorption spectrum shows a peak around 515nm (Figure 8A, 
light green trace), a feature of the absorption spectrum of the Venus fluorescent protein. 
Importantly, the spectrum between 530nm to 670 nm of background lysate and Venus 
lysate overlay well if scaled by a constant value. After background subtraction (after 
scaling, see Methods), the absorption spectrum of the Venus lysate is close to zero 
beyond 530nm (Figure 8A), and overlays well with excitation spectrum of the Venus 
fluorescent protein beyond 470 nm (Figure 8C). While the absorption spectrum is easily 





fluorophore is virtually unaffected by other materials. Indeed, the excitation spectra of 
purified Venus fluorescent proteins and Venus lysate are very similar (data not show). 
Thus, the nice overlay of excitation spectrum of the Venus fluorescent protein and the 
background-subtracted absorption spectrum of the Venus lysate indicates that after 
background-subtraction, the absorption of the Venus lysate is mainly due to Venus 
protein. Accordingly, we can measure the concentration of the Venus-PreIQ3-IQ-A1.3 
peptide in the lysate from the absorption peak, which is 4.68 µM.  Similarly, absorption 
and excitation spectra were measured for lysates from cells expressing both expressing 
Venus-PreIQ3-IQ-A1.3 and Cerulean-ICDI1.4 peptides (dual-fluorophore lysate). We can 
see that after background subtraction, the absorption spectrum of the dual-fluorophore 
lysate also overlays well with the sum of the excitation spectrum of the two fluorophores 
(both excitation spectra were scaled to match the peak of the background subtracted 
absorption spectra) (Figure 8B, D).  Accordingly, the concentration of Venus-PreIQ3-IQ-
A1.3 in the dual-fluorophore lysate was 1.63 µM, and the Cerulean-ICDI1.4 peptide in the 
dual-fluorophore lysate was 4.73 µM.  
Next, we tested whether or not the peptides in lysates bind in a similar manner as 
when expressed in cells. We know that apoCaM binds to the IQ domain of CaV channels, 
and thus serves as a competitive inhibitor of the IQ/ICDI interaction.  In addition, 
Ca2+/CaM binds to the IQ region with higher affinity, and thus can server as a more 
potent competitive inhibitor of the IQ/ICDI interaction. Our hypothesis is that if the 
peptides interact similarly in lysates as in cells, they will have similar FRET ratios (FR) 





fluorophore lysate (Figure 9A, left bar) is the same as the FR of the dual-fluorophore in 
cells (cells from which dual-fluorophore lysate were generated) (Figure 9B, left bar). In 
addition, when Ca2+ is elevated by adding calcium chloride to the lysate, or by applying 
ionomycin to the cells, the FR values of the two decrease to the same level (Figure 9A, 
middle bar vs B, right bar). We suspected that the endogenous expression of CaM is not 
high enough to fully inhibit the IQ/ICDI interaction, even with elevated Ca2+. Thus, we 
used another stable cell line in which CaM is also overexpressed (dual-fluorophore-CaM 
cells). These cells and their lysates have slightly reduced baseline FR values (left bars in 
Figure 9C, D) compared to cells and lysates without CaM overexpression (left bars in 
Figure 9A, B), as expected given that apoCaM is not a very potent competitive inhibitor 
of IQ/ICDI interaction50.  However, when Ca2+ is elevated in either the lysate or the cells, 
the FR values are largely reduced to a very similar level (Figure 9C, middle bar vs D, 
right bar). Moreover, adding additional purified CaM to the dual-fluorophore-CaM lysate 
did not further reduce its FR value. In contrast, adding additional purified Ca2+/CaM to 
the dual-fluorophore lysate (Figure 9A, right bar) further reduces the FR value to the 
same level as the dual-fluorophore-CaM lysate with addition of Ca2+ (Figure 9C, middle 
bar). The consistency of FR values measured for the IQ/ICDI interaction in both the 
lysate and live-cell context, as well as their similar response to competitive inhibitors, 
confirms that both peptides maintain their natural conformation in the lysates, and the 
context for the binding reaction is very similar.  
With evidence that the IQ/ICDI interaction is quite similar in lysates and in intact 





We first obtained the binding curve for the dual-fluorophore lysate. To obtain lysate with 
a lower concentration of the fluorescent-protein-tagged peptides, we diluted the dual-
fluorophore lysate with background lysate (see Lysate-based FRET optical imaging in 
Methods). A binding curved was generated for the dual-fluorophore lysate (Figure 9E). 
From this binding curve and the protein concentrations measured by absorption spectra, 
the dissociation constant of the IQ/ICDI interaction was measured to be 0.12 µM, which 
is about four fold higher than our previous estimation based on guesstimation of optical 
component parameters (Figure 3). From the results from Figure 9A-D, we expect that 
the binding affinities of this interaction should be very similar in cells or in lysates. The 
close agreement of the two values also verifies this point. On the other hand, the same 
interaction measured using the lysate from cells with CaM overexpressed showed a much 
lower binding affinity (Figure 9F, the dissociation constant was measured as 770 µM), 
indicating that this method can take the cellular context of a protein interaction into 
account. Another piece of evidence supporting this idea can be seen in Figure 9G. If we 
diluted the dual-fluorophore lysate with lysis buffer, rather than with background lysate, 
we obtain a different binding curve. This is likely due to some unknown proteins in the 
cellular context affecting this interaction, which most likely serve as mild inhibitors. 
Thus, if we diluted the lysate by lysis buffer, these mild inhibitors were also diluted, 
resulting in an artificially higher measured binding affinity. 
There is a linear relationship between the effective binding dissociation constant 
(Kd,EFF) measured by a live-cell FRET binding assay, and the absolute dissociation 





Kd,EFF  = c ∙ Kd                                                            (2) 
where c is a constant incorporating optical component parameters and cell volume. This 
equation was derived in the supplementary material of Erickson et al14. The basic idea is 
Dfree, which refers to relative concentration of unbound Cerulean-tagged peptide (relative 
free donor concentration), is derived based on the integral of the fluorescence emitted 
from a whole cell assuming a constant cell volume. Thus, the larger the cell volume, the 
higher the measured Dfree corresponding to a certain level of the actual free donor 
concentration. Accordingly, Kd,EFF, which is in the Dfree unit, is also linearly related to cell 
volume. Here we measured Kd,EFF = 1,700 Dfree units, and Kd = 0.12 µM, which allows us 
to estimate the value of c as 14,166 Dfree/µM. As Equation 2 is always true for all binding 
interactions, this calibration allows us to estimate the absolute binding affinities for all 
relative binding affinities measured by the live-cell FRET binding assay in the same cell 
type (HEK293 in our case). To determine c for FRET two-hybrid assays in other cell 
types, the ratio of the cell volume of that cell type and HEK293 cells has to be multiplied 
to multiplied to 14,166 Dfree/µM.  
 
Weak helpers facilitate detection of weak interactions   
FRET two-hybrid assays sometimes fail to detect protein interactions. One 
example is the interaction between the A region and the ICDI region. From our alanine 
scanning study (Chapter 1), it is clear that the A region forms an interface with the ICDI 
region (Figure 4); however, no FRET is detected between the two domains (Figure 1A, 





distance or less favored orientation of the fluorophores (Figure 10A), or a weak binding 
affinity.  How can we resolve these issues? We were inspired by a recent study that 
utilized weak helpers to improve the dynamic range of FRET sensors51. In their design, 
the fluorophores are sandwiched by binding partners of interest and weak helpers (Figure 
10B). These weak helpers are small peptides that bind with low binding affinities 
(dissociation constants between 30µM to above 1000µM) and are irrelevant to the 
binding partners of interest. Without weak helpers, the binding partners interact and bring 
the two fluorophores close to each other, however the fluorophores can still freely tumble 
and move around52, which leads to a larger average distance between the two and thus a 
low FRET efficiency. The weak helpers, whose affinity is too low to cause artificial 
background FRET by themselves, can interact when the binding partners bind and bring 
them close (Figure 10B). The divalent interaction locks the fluorophores close to each 
other in a more constrained configuration, and increases the FRET efficiency. In addition, 
the divalent binding results in a higher binding affinity than either interaction alone, and 
thus can be used to detect weak interactions. A simplified model shows that the affinity of 
divalent binding is proportional to the binding affinity of the weak helpers, from which 
we can estimate the binding affinity of the partners of interest. 
 We first applied this technique to the interaction between IQ1.3 (without A region) 
and ICDI1.4 peptides. From Figure 4B, we know IQ1.3 and ICDI1.4 peptides can bind with 
low affinity but still generate FRET signals. Previously we determined that the effective 
dissociation constant of interaction between IQ1.3 and ICDI1.4 is 60,000 Dfree units (Figure 





to be 4.27µM (see also in Lysate-based FRET assay to measure binding affinity). 
With that, we performed the divalent FRET two-hybrid binding assays between IQ1.3 and 
ICDI1.4 peptides with the flow cytometer (see more in Live-cell FRET binding assay by 
flow cytometry). We first made FRET constructs as shown in Figure 10B, where the red 
shape is the IQ1.3 peptide and the green shape is the ICDI1.4 peptide. Four pairs of weak 
helpers were employed: SH3 domain and its binding peptides Sp1 or Sp2, and the WW 
domain and its binding peptides Wp1 or Wp2.  With the weak helper, we achieved more 
robust FRET signals and higher binding affinities (Figure 11A). As expected, there is a 
linear correlation between binding affinities of the weak helpers and the binding affinities 
measured by the FRET assay (Figure 11B). The slope of the linear fit, which is 0.019 in 
this case, is equal to the ratio of the dissociation constant of the IQ/ICDI interaction and 
the effective local concentration of the weak helpers when IQ and ICDI are bound. 
Accordingly, we can estimate the effective local concentration to be 400µM, which is 
higher than the dissociation constant of the weak helper. The fact that the weak helpers 
have dissociation constants between 30-170µM has two main advantages: they are not 
too high to cause background FRET, and they are high enough to form divalent binding 
when the peptide of interest binds.  
Next we performed the divalent FRET two-hybrid binding assay between A1.3 and 
ICDI1.4 peptides. We know that we cannot detect any binding without a weak helper (see 
Chapter 1). Now, with the weak helper, we were able to obtain binding curves (Figure 
12A). Similar to Figure 11B, there is a linear correlation between the binding affinities of 





Assuming the local concentration of weak helpers is around 400µM, we estimate that the 
dissociation constant between A and ICDI peptides is about 10µM, similar in strength to 
the IQ/ICDI interaction. Thus, the A region indeed binds to the IQ region; however two 
factors appear to inhibit our ability to detect this binding via standard FRET two-hybrid 
assays: (1) the binding affinity is at the limit of detection using the FRET binding assay, 
and (2) the A region is much bulkier than the IQ region and likely creates significant 
steric hindrance preventing the fluorophores from remaining in close proximity. 
Nonetheless, with the aid of a weak helper, we now can estimate the binding affinity of 
this interaction. 
FRET-based HTS for molecules interfering with protein interactions 
The IQ/ICDI interaction serves as a prototypic target for high-throughput 
screening, for two reasons. First, we have extensively characterized this interaction. The 
binding affinity of this interaction is at a desired range where overexpression in 
heterologous systems can easily saturate the binding, providing an optimal FRET 
readout, and perturbation is readily observable. In addition, the systematic alanine 
scanning done in Chapter 1 suggests that individually disrupting distinct and distributed 
segments of the IQ/ICDI interface suffices to disrupt the global interaction and its 
function (Figure 5D, V[1888] and I[1893] on ICDI, F[4] on IQ). Thus, it is very likely 
that a small molecule could substantially impact this interaction without requiring 
simultaneous disruption of the majority of the contact interface. More importantly, while 
pharmaceutical compounds modulating the gating of L-type Ca2+ channels (CaV1 class) 





of CaV1 channels, despite growing awareness of subtype-specific roles in physiology and 
pathophysiology as well as significant effort devoted to searching for such molecules. 
This impasse results in part from the high degree of homology among CaV1 subtypes. A 
recent report by Kang et al. reported the discovery of a CaV1.3 specific antagonist54, 
however the specificity of the compound has been disputed by later studies55,56.  Thus, 
subtype specific ICDI modulation of CDI looms as an attractive target for the discovery 
of selective small-molecule modulation of CaV1.3 channels.  Such a compound promises 
great pharmaceutical potential, as CaV1.3 is proposed to be a major source of Ca2+ 
toxicity in Parkinson’s disease57. 
As a first step towards translating our microscope-based assay of IQ/ICDI 
interactions into a high-throughput plate-reader format, we created stable HEK293 cell 
lines expressing relevant FRET pairs and fluorophore controls. The reason we used 
separate fluorescent tagged IQ and ICDI peptides instead of a unimolecular sensor 
composed of both peptides is to maximize the FRET signal change caused by potential 
IQ/ICDI disrupting compounds. As a single dosage would be used in the primary screen 
of a large number of candidate molecules, it is possible that some molecules may only 
partially disrupt the binding at the test dosage.  If the fluorophores are covalently linked 
in a unimolecular configuration, they might still be close enough to each other when the 
binding is partially or even largely disrupted, producing a small change in the FRET 
signal and potentially giving in a false negative result. With the peptides expressed 
separately, we expect to get larger FRET signal changes in response to interaction 





unimolecular sensor is to express the peptides at a level where binding is just saturated, 
which allows the largest FRET change due to binding interference by a small molecule.  
To make stable cell lines with the optimal expression level, we used lentivirus to integrate 
the genes of interest into the host genome. The advantage of using lentivirus, rather than 
traditional resistance selection, is that cells with various level of expression can be 
generated by titrating the amount of virus used for infection58. Then, by single colony 
selection, we can identify cell lines with desired expression level of fluorescent proteins.  
Microscope-based FRET characterization of these stable lines is displayed in 
Figure 13A. Cells expressing Cerulean and Venus as separate molecules yielded 
negligible binding, as viewed on the same binding-curve display format (Figure 13A, 
green symbols). By contrast, cells expressing a Cerulean-Venus dimer exhibited 
uniformly high FRET (red symbols). For cells stably expressing the Venus-PreIQ3-IQ-
A1.3 and Cerulean-ICDI1.4, data points were reassuringly situated on the plateau phase of 
the binding curve (Figure 13A, black symbols), with a binding-curve fit from data from 
the same wild-type FRET pairs transiently expressed in HEK293 cells (green curve, 
Figure 2A) reproduced for reference. Also gratifying was the sharp drop in FRET in 
these cells (Figure 13A, blue symbols), upon coexpressing CaM and elevating Ca2+ with 
ionomycin to disrupt the IQ/ICDI interaction via competition8. The difference between 
the black and blue data thereby gauges the dynamic range of our assay. Because of the 
position of the IQ/ICDI interaction data on the plateau of binding curves, all of these 
outcomes could be converted into an aggregate bar-graph format (Figure 13B), more 





that in Figure 13A, and z scores and S/N ratio computed for the observed dynamic range 
are remarkably good. We next assayed these same stable cells on a tecan safire multi-well 
plate reader, with the help of Meng Wu at the Johns Hopkins Ion Channel Center 
(JHICC). Characterization of cells expressing Cerulean or Venus alone yielded FRET-
conversion parameters (RA and RD, used to calculate FR7,14,59) that were highly similar to 
those obtained on our microscope platform (Figure 13C). Importantly, controls and 
IQ/ICDI interactions yielded results in the plate-reader format (Figure 13D) that were 
similar to those obtained on the microscope-based platform (Figure 13B). Dose-
dependent augmentation of intracellular Ca2+ with ionomycin yielded a smoothly-graded 
decrease in IQ/ICDI FRET (Figure 13E), engendering confidence in the robust z scores 
and S/N ratio calculated for the plate-reader format (Figure 13D, F). 
Thus encouraged, we undertook a preliminary 1280-compound screen (LOPAC 
library) for candidate IQ/ICDI disrupters, again with the help of Meng Wu at the Johns 
Hopkins Ion Channel Center (JHICC) (Figure 14). Panel A shows the layout for a single-
multi-well plate and panel B shows the results of the LOPAC screen in a heat-map 
format. The IQ/ICDI FRET interaction in the presence of various compounds appears in 
columns 3-22. Fluorescence controls are in columns 1-2, and ionomycin gradients 
confirming the dynamic range of the assay are in columns 23-24 (see legend and Methods 
for details). Most of the IQ/ICDI wells showed FRET FR values ~10, demonstrating the 
consistency of IQ/ICDI FRET in the absence of hits. Panel B displays the results from 
multiple plates in a linear graphical format, where the x-axis plots compound number, and 





candidate hits (Figure 14C, red symbols), yielding substantial decrements in the FRET 
metric FR. Their chemical compositions are reproduced below the corresponding 
symbols. Two of the potential hits are also visualized in Figure 14B as cyan-colored 
wells in columns 3 and 5. By contrast, some compounds increased apparent FRET (gray 
symbols), likely due to spurious fluorescence of the added compound. We favor this 
interpretation because FRET-channel signals increased without a concomitant Cerulean-
channel decrease, as would be expected of a bona fide increase in FRET.  Overall, the 
results of this provisional LOPAC library screen bolster confidence in the feasibility of a 
large-scale screen. 
With the above preliminary studies, we were supported by a RO3 grant to screen 
small molecules that disrupt the IQ/ICDI interaction of CaV1.3/1.4 channels, using the 
MLSMR library of 350,000-500,000 compounds. We collaborated with the Broad 
Institute Probe Development Center (BIPDeC) for the primary screen. As BIPDeC did 
not have a tecan safire plate reader, we performed the assay on a Perkin Elmer 2102 
Envision Instrument. We first tested the ionomycin response of our stable cell lines (the 
same experiment as Figure 13D). With the help of Carl Apgar at Perkin Elmer, we were 
able to optimize the instrument to reduce the integration time of signal detection to 1 
second, crucial for screening the large compound library in a reasonable amount of time.  
Moreover, we achieved better performance in terms of signal to noise ratio as compared 
to the tecan safire plate reader. 
As small molecules affecting fluorescent proteins Venus or Cerulean, or 





genuinely disrupting the IQ/ICDI interaction, counter-screens were designed for 
eliminating such molecules. To counter-screen small molecules affecting the fluorescent 
proteins, a stable cell line expressing a Cerulean-Venus dimer was created by a traditional 
resistance selection method. Lentivirus cannot be used to generate cell lines expressing 
two covalently linked fluorophores, due to the recombination of the closely related 
fluorescent protein sequences in the viral DNA60. To counter-screen small molecules 
perturbing intracellular Ca2+ concentrations, use of a Ca2+ dye is proposed. Although 
stable cell lines maintain the desired expression level for at least 20 to 30 passages, the 
expression level eventually would diminish after many passages or multiple rounds of 
freeze and thaw. Unfortunately, cell lines sent to BIPDeC were subjected to excessive 
freeze/thaw cycles, resulting in a degraded signal to noise ratio in their ionomycin 
response before starting the MLSMR library screen. In addition, time constraints meant 
that the planned counter screens could also not be performed.  Nonetheless, the scree 
produced several potential hits, and we tested four compounds in their top hit list 
(http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?q=&aid=743397), which did not show 
obvious perturbation of the fluorescent proteins. Those compounds all reduced the FRET 
signal of the stable cell lines, but did not pass the counter screens: two compounds 
affected the fluorescent proteins and two compounds elevated intracellular calcium 
concentration. 
Live-cell FRET binding assay by flow cytometry 
While three-cube FRET binding assays on wide-field and confocal microscope 





measuring their relative binding affinities in multiple studies 27,40, it is labor intensive and 
time consuming.  A high throughput three-cube FRET binding assay is highly desirable 
for identification of protein interactions on a large scale. In collaboration with Shin Rong 
Lee (Calcium Signals Lab, Johns Hopkins), we adapted the 3-cube FRET binding assay 
to a flow cytometry platform. Flow cytometers can quickly screen multiple cells, and 
with that, we can build a binding curve in one-hundredth of the experimental time 
compared to a microscope setup, generating many more data points.  
Calibration of the flow cytometer to obtain the necessary parameters were 
performed by Shin Rong Lee49. To prove that comparable results can be obtained with a 
flow cytometer as compared to a microscope-based method, we repeated FRET binding 
assays for several mutants used in the alanine mutagenesis studies (Chapter 1). It is clear 
that we can obtain similar binding curves with many more data points with the new flow 
cytometer setup (Figure 15A-C). Moreover, the relative binding affinities measured by 
both setups are very similar (Figure 15D). 
Discussion 
There are two major approaches for measuring the binding affinities of protein 
interactions: chemical assays or optical assays61. Chemical assays usually require protein 
purification, which is not feasible for many proteins, especially large membrane proteins. 
In fact, we found it was even challenging to purify the small segments from the 
intracellular domain of CaV channels. In order to obtain a sufficient amount of starting 
material, we tried to express these constructs in bacterial expression system, but found 





the bacterial expression system and in vitro testing environment are very different from 
the cellular context, so the binding affinities measured for protein interactions by 
chemical assays might not be the same as that in native context, especially for 
mammalian protein targets. On the other hand, as the target proteins are purified, it is 
easy to measure their concentration, and thus measure the absolute binding affinity in 
molar units. Moreover, as it is easier to manipulate the concentration of proteins in in 
vitro, people can accurately measure binding affinities spanning from picomolar to 
millimolar range. The optical assays, on other hand, have major benefits over in vitro 
assay as they can quantitatively measure protein binding affinities in live cells. Thus, 
tedious protein purification issues can be totally avoided. More importantly, these assays 
can be applied in different cell types, allowing observation of the regulation of binding 
affinity in specific cell types (Chapter 3).  
However, one major constraint of optical assays comes from the complicated 
optical system, which is hard to calibrate and obtain absolute binding affinities. In this 
study, we developed a lysate-based FRET two-hybrid binding assay, which can measure 
the absolute binding affinities without protein purification. We used absorption spectra to 
measure the concentration of fluorescent proteins. Even though the endogenous cellular 
context can contribute to the absorption spectrum, they tend to have low absorption at 
high wavelengths, where the fluorescent protein, especially Venus, has its feature peak. 
With careful background subtraction, we confirmed that the remaining absorption is 
caused solely by the fluorescent protein, as the corrected absorption spectra overlap well 





protein is the same as the peptide to which it is tagged, i.e. no degradation and proteolysis 
happens. This was confirmed by a western blot (data not shown).  
Now the major concern is the similarity of the live cell environment and the cell 
lysate. Inevitably, lysing the cell destroys many cellular organelles and exposes the 
intracellular proteins to the air. Here, by carefully selecting a lysis solution which is very 
close to the intracellular solution, and using a minimal amount of lysis solution, we 
attempted to keep the environmental changes and dilution effects on the cellular content 
as little as possible. One underlying assumption of the live-cell FRET two-hybrid assay is 
that the fluorescent protein tagged binding partners are homogeneously distributed in the 
cytosol. Thus, disruption of cellular organelle is less likely to affect the interaction; 
however, disruption of the cytoskeleton and changes in solubility of some endogenous 
proteins due to lysis might be more problematic. Luckily, our binding partners were not 
significantly affected by these issues (Figure 9A-D). One thing to be noticed is that the 
protein binding partners have to be expressed at a high level, allowing us to use dilution 
in order to obtain the entire binding curve. As the expression level required is relative to 
the binding affinity, this method is not suitable for weak interactions. Here, we used 
stable cell lines since all cells have similar and sufficient expression, but high expression 
can also be achieved by efficient transfection62 and lentiviral induction. As there are 
several constraints, not all binding partners will be suitable for the lysate FRET assay. 
However, paired with a live-cell binding assay of the same protein interaction, it allows 
us to calibrate the optical platform (Equation 2), and measure the absolute value of the 





  Another constraint of live-cell FRET binding is that it can only measure binding 
affinities within a narrow range (between tens of nanomolars and a few micromolars). 
Higher binding affinities cannot be accurately measured due to instrumental limitations. 
More specifically, in order to resolve the initial phase of a binding curve, we need to 
measure cells expressing FRET constructs at the level of the binding affinity or lower. 
The averages radius of HEK293 cells was measured as 7.7 µm49, from which we can 
estimate that the average cell volume is about 2 picoliter. Thus, to reach 1 nM expression 
level of a construct, we need cells expressing only ~1000 fluorescent proteins, and in our 
FRET experiment, the excitation power is low enough that only a small percentage of  
fluorophores are excited at a time (see supplementary materials of Erikson et al., 200114). 
In other words, we need to accurately measure signals from tens of fluorescent proteins, 
which is very difficult.  However, in such case, we can at least tell the protein interaction 
occurs with a very high binding affinity by FRET two-hybrid, even though we cannot 
give very accurate measurement of the binding affinity. So this limitation is not a big 
problem. On the other hand, lower binding affinities cannot be detected as the cellular 
machinery usually can only produce exogenous proteins up to a few micromolars. Also, 
very high expression levels make cells sick or cause aggregation of fluorescent proteins, 
rendering FRET assays inapplicable.  As described previously, these low affinity binding 
interactions can be of significant functional importance. Of note, yeast two hybrid63, 
another popular live-cell binding assay, allows for the detection of weak protein 
interactions between transcription factors, as its readout tends to be amplified through 





we can use weak helpers to create divalent binding, which results in higher binding 
affinities suitable for measurement by FRET two-hybrid assays. The strategy of using 
divalent binding to generate high affinity interactions is employed by the nature, for 
example in the function of antibodies64. Models of divalent binding have been 
extensively studied65,66. Here, by choosing weak helpers with binding affinities within a 
favorable range, we can use a simplified model to estimate the binding affinity of the 
target protein interaction from the measured divalent binding affinity. One caveat here is 
that the effective local concentration of weak helper in the protein complex is needed for 
estimating the binding affinity. In this case, we assume the concentration is about 500µM 
as we expect the protein complex is relatively small. However, this method could be 
further improved by developing a good way to measure this value for various protein 
interactions of interest. 
It has been a field-wide challenge to find small molecule compounds that disrupt 
specific protein interactions67,68. While in vitro high-throughput screening (HTS) for 
inhibitors is more straightforward69, it tends to produce false-positive results because of 
lack of cell context70. Hits might only inhibit the protein interaction in the highly artificial 
in vitro environment or may not pass through the membrane so they cannot affect 
intracellular protein interactions. That said, our proposed live-cell FRET-based assay 
represents a novel approach, one that concurrently screens for membrane permeability 
and disruption of binding.  It has several advantages over the previously developed cell-
based protein fragment complementary assays such as yeast/mammalian two-hybrid71 or 





fragment complementary reaction assays, FRET is reversible and thus more suitable for 
detecting inhibitors of protein interactions. Second, FRET is ratiometric, and the values 
obtained do not rely on absolute readings and thus have lower inter-well variation. 
However, it is often thought that cell-based FRET two-hybrid assays are not suitable for 
HTS due to a small signal to noise ratio73. On one hand, the FRET signal is weak and can 
be mixed with crosstalk due to direct fluorescence, and thus requires careful calibration. 
On the other hand, it could be challenging and time consuming to design optimal FRET 
constructs. While unimolecular FRET sensors seems to be attractive, they are hard to 
design and optimize. Moreover, it is hard to predict how much FRET reduction can be 
caused by inhibitors, especially if partially disrupted by weak inhibitors. Bimolecular 
FRET, on the other hand, might enjoy better signal to noise ratio as disruption of binding 
leads to no FRET. The challenge of bimolecular FRET is to have the two binding partners 
expressed at the desired level in all cells. It turns out that by using lentivirus, we can 
reach the desired expression level much more precisely than by using the traditional 
resistant selection. The stable cell lines produced by lentivirus can maintain fairly 
homogenous expression levels at the population level for several months. In this study, 
we manually selected single colonies to form stable cell lines. In the future, flow 
cytometry can be used to expedite this process. Of note, however, lentivirus has potential 
recombination issues60, and the expression level of stable cell lines can degrade after a 
few freeze and thaw cycles or repeated passaging. 
One potential issue in the use of FRET-based HTS assays are the artificial FRET 





fluorophores (Figure 14C). This problem can be largely solved by using couterscreens on 
cell lines expressing Cerulean-Venus dimers. In summary, our FRET-based HTS assay 
provides an inexpensive venue with which to detect inhibitors of protein interactions in 

























Figure 8. Using absorption spectrum to determine fluorescent protein concentration.  
(A) Absorption spectrum of lysate from cells that do not express fluorescent proteins 
(background, gray trace) and cells expressing Venus-PreIQ3-IQ-A1.3 peptide (Venus lysate, 
light green trace). Subtracting the spectrum of background (after scaling by a constant 
value) from that of Venus lysate gave the spectrum shown in green. (B) Absorption 
spectrum of lysate from background (gray trace) and cells expressing Venus-PreIQ3-IQ-
A1.3 peptide and Cerulean-ICDI1.4 peptide (dual-fluorophores lysate, light purple trace). 
Subtracting background from dual-fluorophore lysate gave the spectrum shown in dark 
purple. (C) Overlay of absorption spectrum of Venus lysate (green trace, background 
subtracted, same as in A) with excitation spectrum of Venus (dark green trace). Both 
spectrum were scaled. (D) Overlay of absorption spectrum of dual-fluorophore lysate (dark 
purple, background subtracted, same as in B) with excitation spectrum of Venus (dark green 
trace), Cerulean (cyan trace) and the addition of the two (light purple trace). The excitation 






















Figure 9. Using lysate FRET to determine binding affinity of IQ/ICDI interaction. 
 (A) Lysate of cells expressing Venus-PreIQ3-IQ-A1.3 peptide and Cerulean-ICDI1.4 peptide 
(dual-fluorophore lysate) shows high FR (no add), reduced FR when Ca2+ is added (+Ca2+) 
and further reduced FR when purified CaM protein added (+CaM). (B) Cells expressing 
Venus-PreIQ3-IQ-A1.3 peptide and Cerulean-ICDI1.4 peptide (dual-fluorophore cells) 
shows high FR (no add) and reduced FR (+iono) when internal Ca2+ is elevated by adding 
ionomycin.  (C) Lysate of cells expressing Venus-PreIQ3-IQ-A1.3 peptide and Cerulean-
ICDI1.4 peptide and overexpressing CaM (dual-fluorophore-CaM lysate) shows high FR 
(no add), largely reduced FR when Ca2+ is added (+Ca2+) and no further reduced FR when 
purified CaM protein added (+CaM). (D) Cells expressing Venus-PreIQ3-IQ-A1.3 peptide 
and Cerulean-ICDI1.4 peptide and overexpressing CaM (dual-fluorophore-CaM cells) 
shows high FR (no add) and largely reduced FR (+iono) when internal Ca2+ is elevated by 
adding ionomycin.  (E) Two-hybrid FRET assay on dual-fluorophore lysate. Fluorescent 
lysate was diluted by lysate from background cells (background lysate) to obtain lower left 
points on the curve. (F) Two-hybrid FRET assay on dual-fluorophore-CaM lysate (red). 
Similar as C, fluorescent lysate was diluted by background lysate to obtain lower left points 
on the curve. The blue curve are the same curve in C. (G) Two-hybrid FRET assay on dual-
fluorophore lysate. The lower left points on the curve were obtained by diluting the dual-
fluorophore lysate with background lysate (blue) or lysis buffer (red). The blue trace is 
different from the blue trace in E and F is because this experiment was performed on a 












Figure 10. Cartoon of weak helper improving FRET.  
(A) Fluorophores (blue and yellow barrels) are separated by the complex formed by 
interaction between the two peptides (red and green complementary shapes).  Such 
configuration results in low FRET. (B, C) Weak helpers (dark green nicked circle and blue 
bar) were attached to fluorophores. These weak helpers are low affinity binding partners 
which only binds when the peptides of interest (read and green complementary shapes) 
binds and bring them close to each other. Binding of weak helpers (C) restrains the free 














Figure 11. Divalent FRET binding assay of IQ and ICDI interaction using weak 
helpers.  
(A) Interaction of IQ and ICDI peptides measured by divalent FRET two-hybrid binding 
assays utilizing weak helpers. The design of constructs can be represented by cartoon in 
Fig. 10B, where the red shape is IQ1.3 and the green shape is ICDI1.4. Four pairs of weak 
helpers were tested, SH3 domain and its binding peptides Sp1 or Sp2, WW domain and its 
binding peptides Wp1 or Wp2. (B) Correlation between binding affinity measured by 
FRET two-hybrid assay and the affinity of weak helper pairs. Color scheme is the same as 
in A. The binding affinity of SH3/Sp1, WW/Wp1, WW/Wp2 were measured as 30, 50, 170 
µM51, but here 70 µM is used as binding affinity of WW/Wp1 instead of 50 µM as it fits 
better for both IQ/ICDI and A/ICDI experiments. The binding affinity measured by FRET 
two-hybrid assay employing SH3/Sp1, WW/Wp1, WW/Wp2 as weak helpers are  0.42, 
0.84, 1.81µM. The binding affinity of SH3/Sp2 is not known but estimated as > 1000 µM51, 
so its data is not included on this plot. The black line is a linear fit with the slope of 0.0109. 











Figure 12. Divalent FRET binding assay of IQ and A interaction using weak 
helpers.  
(A) Interaction of A and ICDI peptides measured by divalent FRET two-hybrid binding 
assays utilizing weak helpers. The design of constructs can be represented by cartoon in 
Fig. 10B, where the red shape is A1.3 and the green shape is ICDI1.4. Four pairs of weak 
helpers were tested, SH3 domain and its binding peptides Sp1 or Sp2, WW domain and 
its binding peptides Wp1 or Wp2. (B) Correlation between binding affinity measured by 
FRET two-hybrid assay and the affinity of weak helper pairs. Color scheme is the same 
as in A. The binding affinity of SH3/Sp1, WW/Wp1, WW/Wp2 were measured as 30, 50, 
170 µM51, but here 70 µM is used as binding affinity of WW/Wp1 instead of 50 µM as it 
fits better for both IQ/ICDI and A/ICDI experiments.  The binding affinity measured by 
FRET two-hybrid assay employing SH3/Sp1, WW/Wp1, WW/Wp2 as weak helpers are  
0.35, 1.24, 2.89µM. The binding affinity of SH3/Sp2 is not known but estimated as > 
1000 µM51, so its data is not included on this plot. The black line is a linear fit with the 














Figure 13. Translating FRET binding assay from microscope-based to plate-reader 
format. 
 (A) Microscope-based assay of constructs expressed in stable cell lines. Each symbol 
corresponds to a single stable cell expressing constructs given by the following color 
code: red, Cerulean-Venus dimer; black, Venus-PreIQ3-IQ-A1.3 and Cerulean-ICDI1.4; 
blue, Venus-PreIQ3-IQ-A1.3, Cerulean-ICDI1.4, CaM in presence of ionomycin; green, 
Cerulean and Venus expressed as separate molecules. (B) Mean values of cells in A, 
along with z and S/N ratio. Same color code. (C) FRET conversion parameters on 
microscope and safire2 plate reader. (D) Plate-reader results, each group averaged from 3 
wells. Color code as in B. (E) Titration of ionomycin on ‘blue-type cells’ in B, measured 
on safire2 plate reader. (F) Statistics for experiment in D, repeated in four additional 

































Figure 14. Provisional 1280-compound LOPAC library screen. 
 (A) Results, single multi-well plate, in heatmap format (FRET metric FR color-coded as 
shown at bottom). Columns 3-22 show IQ/ICDI interactions subject to various compounds 
at 25 µM. olumns 1-2; A-D, background cells; E-H, cells with Venus; I-L, cells with 
Cerulean; CM-P, cells with ICDI/IQ and no drug. Columns 23-24: A-H, ICDI/IQ cells with 
ionomycin gradient (13, 4.4, 1.5, .5, .2, .06, .02, .01 µM, respectively; I-P, same as A-H 
minus CaM. (B) Linear graphical display of results for 1280-compound LOPAC screen. 
Histogram at right indicates tight distribution of most of the wells around a FRET readout 
value of ~10 (green dash line). Red dashed line shows mean – 3.5x standard deviations, 
which correspondence to threshold for marking ‘hits,’ as exemplified by 3 red symbols. 
Affiliated compound structures are shown below. Some compounds increased apparent 
FRET values, as shown by gray symbols. We believe these to reflect spurious compound 
fluorescence, rather than a genuine enhanced ICDI/IQ interaction. Note axis break and 
































Figure 15. Comparison of 3-cube FRET binding assay on microscope and flow 
cytometer.  
(A, B, C) FRET two-hybrid assays were performed for interaction between Venus-PreIQ3- 
IQ-A1.3 peptide and Cerulean-ICDI1.4 peptide on microscope (middle column, A, B, C) and 
flow cytometer (right column, A, B, C).  In addition to wide-type peptides, hotspot on IQ 
region (A), ICDI region (B) and A region (C), indicating by the start on the cartoons (left 
column, A, B, C),  are tested. (D) Relationship of normalized dissociation constants 
measured on microscope (Kd_microscope) and those measured on flow cytometer (Kd_facs). The 
color scheme is the same of in A, B, C. Dissociation constant of wild-type peptides 
measured for each method was used for normalization (i.e., the green dot has both 





















Phosphorylation, as one of the most ubiquitous forms of post-translational 
modification, plays essential roles in biological functions74. Traditionally, 
phosphorylation sites were identified by phosphopeptide mapping and Edman 
degradation sequencing75. With the recent progress of mass spectroscopy based 
proteomics, numerous potential phosphorylation sites can now be identified76,77. 
However, establishing the biological relevance and underlying molecular pathway of 
these phosphorylation sites remains difficult78, especially for large membrane proteins 
such as voltage gated ion channels. In particular, the regulation of L-type Ca2+ channels 
by PKA, though biologically crucial, has long remained mechanistically storied and 
complex78-80. While native cells feature full-bore PKA regulation of L-type Ca2+ 
channels, it has been difficult to dissect out the critical factors of this regulation among 
the vast array of native molecules81. On the other hand, in vitro biochemistry can 
sometimes identify sites that do not correlate with function76. The use of a recombinant 
system such as HEK293 cells has therefore become a valuable method for characterizing 
phosphorylation pathways and elucidating the functional relevance of potential 
phosphorylation sites77,82. Unfortunately, such a model system for studying the PKA 
modulation of L-type Ca2+ channels has remained challenging as even the strong PKA 
enhancement of cardiac CaV1.2 L-type Ca2+ channels cannot be fully reconstituted in 
heterologous systems78,80,83. 
Here, we adopt a different tactic and utilize ideas drawn from synthetic biology 





strategy is based on perturbing the calmodulation of L-type Ca2+ channels84. Calmodulin 
(CaM) is known to associate with the IQ domain of the channel carboxy terminus while 
in the Ca2+ free (apo) state14,22. The presence of apoCaM on the channel IQ significantly 
increases channel open probability (PO) as compared to the channel in the absence of 
apoCaM6 (Figure 1A). In addition, the presence of apoCaM enables Ca2+/CaM 
dependent inactivation (CDI), whereby Ca2+ binding to the resident CaM results in a 
decrease in channel PO22. This effect can readily be seen in whole cell experiments where 
channels bereft of CaM exhibit diminutive but sustained currents, while channels 
populated by CaM have significantly larger peak current amplitudes and robust CDI. 
Several L-type channel splice variants exploit this calmodulation effect in order to 
tune the biophysical properties of channels expressed in different cell types34,85,86. In 
particular, long splice variants of CaV1.3 and 1.4 channels contain a CDI-inhibiting 
module (ICDI) within their distal carboxyl terminus (DCT) which competes with 
apoCaM for binding at the IQ domain8,9. By dislodging CaM, ICDI profoundly 
suppresses the channel open probability and eliminates CDI. We reasoned that a 
phosphorylation site in ICDI might weaken it’s affinity for the IQ domain in a PKA-
sensitive manner, allowing channels to rebind CaM and thus undergo an increase in 
current amplitude and CDI.  
We therefore explored if such a PKA phosphorylation site might exist natively 
within the ICDI domain via a live-cell FRET two-hybrid assay in adult guinea pig 
ventricular myocytes (aGPVMs). Remarkably, we found that the IQ interaction with the 





activation, whereas ICDI modules from other L-type channel isoforms (CaV1.2 and 1.3) 
showed no such modulation. Accordingly, we synthesized chimeric CaV1.3 channels 
fused to ICDI1.4, and endowed these channels with robust forskolin-dependent 
enhancement of open probability and CDI, observable in HEK293 cells. The modularity 
of this synthetic PKA regulation of L-type Ca2+ channels was further demonstrated by 
strong PKA regulation of CaV1.2 channels with ICDI1.4 co-expressed as a peptide. Finally, 
we demonstrated that PKA can modulate the current amplitude and CDI of wild-type 
CaV1.4 channels in HEK293 cells and identified S1883 as the phosphorylation site within 
CaV1.4 via mass spectroscopy and site directed mutagenesis. In all, PKA modulation of 
CaV1.4 Ca2+ channels, discovered through a synthetic live-cell biochemical approach, 
might be an important regulatory mechanism utilized by CaV1.4 channels, enabling 




Molecular biology. The CaV1.3 channel (in pcDNA6) was derived from the rat 
brain variant (AF307009.1)20. CaV1.2 (in pGW) is identical to rabbit NM00113652221, 
and CaV1.4 (in pCDNA3) is the human clone corresponding to NM007186. CaV1.3S/1.4DCT 
(in pcDNA6) was made by fusing with the DCT of CaV1.4 to the CaV1.3 channel 
backbone (truncated after the IQ domain), as previously described8. To generate the point 
mutation (S1883A) in the CaV1.3S/1.4DCT chimeric channel, the mutation was first 





(Agilent) before PCR amplification and insertion into the CaV1.3 channel backbone, 
using the same strategy as the wild-type CaV1.3S/1.4DCT chimeric channel. β2a-Gly8-CaM 
(in pcDNA3) was made as described before42, and used in experiments for Figure 27; 
β2a-Gly32-CaM was made by extending the number of glycine residues in the linker from 
8 to 32, using similar strategies as described before5, and used in experiments for Figure 
24; β1b-Gly32-CaM was made by swapping β2a (M80545)87 with β1b (NM_017346.1)88 
via KpnI and NotI sites, and used in experiments for Figure 25.  
FRET constructs were fluorescent-tagged (either Venus or Cerulean) using similar 
strategies as previously described14. Briefly, Venus and Cerulean fluorophores (a kind gift 
from Dr. Steven Vogel at NIH) were subcloned into pcDNA3 via unique KpnI and NotI 
sites. The PCR-amplified channel peptides as described in Liu et. al.8 were then cloned in 
via unique NotI and XbaI sites. The fluorescent-tagged peptides were PCR-amplified as a 
whole and cloned into pAdLox via KpnI and EcoRI.  
In order to make the Venus-PKAca-P2A-PKAr2b-Cerulean construct, Cerulean 
was PCR amplified and cloned into pcDNA3 via XbaI/ApaI, and then PKAr2b (Addgene: 
pDONR223-PRKAr2b) was PCR amplified (the P2A sequence, 
FQGPGATNFSLLKQAGDVEENPGPSLSK, was fused 5’ of PRAr2b by this PCR 
amplification) and cloned via NotI/XbaI. PKAca (Addgene: pDONR223-PRKACA) was 
first cloned into Venus-C1 (made by replacing EGFP by Venus in pEGFP-C1) as 
described49. The Venus-PKAca was then PCR amplified and cloned into pcDNA3 





fluorescent tag) was PCR amplified using Venus-PKAca-P2A-PKAr2b-Cerulean as a 
template and inserted into pcDNA3 via KpnI and XbaI. 
Adenovirus production. Adenoviral vectors were generated using the Cre-Lox 
recombination system as previously described1. Briefly, pAdLox plasmids encoding the 
FRET binding partners were co-transfected with Ψ5 vector into Cre8 cells, allowing 
expression and packaging of the viral particles. After three-rounds of expansion in Cre8 
cells, a final viral amplification was done in HEK293 cells. The viral particles were 
collected and purified by a standard CsCl gradient protocol. The purified viral stock had a 
titer of at least 1012 particles/µl. 
aGPVM culture and infection. Adult guinea pig ventricular myocytes 
(aGPVMs) were isolated as described48,76 and plated on laminin-coated glass coverslips 
in M199 media containing 20% fetal bovine serum (FBS). After 1 hour, media was 
exchanged with 0% FBS M199 media and adenoviruses encoding FRET binding partners 
were added. 8 to 12 hours later, the myocytes were washed once with warmed PBS, and 
the media was replaced with fresh 0% FBS media. aGPVMs were imaged within 24 
hours of isolation.  
Transfection of HEK293 cells. For electrophysiology experiments, HEK293 
cells were cultured on 10-cm plates, and channels were transiently transfected by a 
calcium phosphate protocol22. We applied 4-16 µg of plasmid DNA encoding the desired 
α1 subunit, as well as 6-8 µg of β and 5-8 µg of rat α2δ (NM012919.2)23 subunits along 
with 3 µg of SV40 T antigen. For forskolin incubation experiments, β2a without a glycine 





PKAr2b-Cerulean were co-transfected. For dynamic forskolin wash-on experiments, a β 
subunit (β2a for CaV1.3 and 1.4; β1b for CaV1.2) with glycine linked CaM was used. In 
addition, 4 µg Venus-PKAca-P2A-PKAr2b-Cerulean, 1 µg PKAr2b-Cerulean and 3 µg 
AKAP79 (M90359.1) were co-transfected. Generally, β2a was chosen to minimize the 
confounding effects of VDI, thus maximizing the dynamic range of CDI. For CaV1.2 
channels, β1b was used in order to closely recapitulate the behavior of the native CaV1.2 
channel expressed in cardiac cells. By decreasing the dynamic range of observable CDI, 
this perturbation also increased the stringency of the test and allowed for comparison 
with native PKA modulation of CaV1.2 channels (Figure 26). 
For microscope-based FRET assays, HEK293 cells cultured on 3.5-cm culture 
dishes with integral No. 0 glass coverslip bottoms (In Vitro Scientific) were transiently 
transfected with polyethylenimine (PEI) reagent (Polysciences). For flow-cytometer-
based FRET assays, HEK293T cells cultured on 6-well plates were transiently transfected 
with PEI. All of constructs were driven by a cytomegalovirus promoter. Experiments 
were performed 1-2 days following transfection. 
Whole-cell electrophysiology recording. Whole-cell recordings were obtained at 
either room temperature or 30°C as described using a TC-10 heating & cooling 
temperature controller (Dagon Corporation) and Axopatch 200A amplifier (Axon 
Instruments). Electrodes were pulled from borosilicate glass capillaries (Word Precision 
Instruments), with 1-3 MΩ resistances, which were in turn compensated for series 
resistance by >60%. Currents were low-pass filtered at 2 kHz before digital acquisition at 





contained (in mM): CsMeSO3, 114; CsCl, 5; MgATP, 4; HEPES (pH 7.4), 10; and 
BAPTA (1,2-bis(o-aminophenoxy)ethane- N,N,N’,N’-tetraacetic acid), 10; at 295 mOsm 
adjusted with CsMeSO3. The bath solution was (in mM): TEA-MeSO3, 102; HEPES (pH 
7.4), 10; CaCl2 or BaCl2, 40; at 305 mOsm adjusted with TEA-MeSO3. 
Microscope-based FRET optical imaging. FRET two-hybrid experiments were 
performed on an inverted microscope as described7,14. The bath Tyrode’s solution was (in 
mM): NaCl, 138; KCl, 4; MgCl2, 1; HEPES (pH 7.4), 10; CaCl2, 2; at 305mOsm adjusted 
with glucose. Background fluorescent signals were measured from cells without 
expression of the fluorophores, which was particularly important for experiments in 
aGPVMs due to higher autofluorescence. In Hek cells, concentration-dependent spurious 
FRET was subtracted from the raw data prior to binding-curve analysis7,14. Cerulean and 
Venus were used as the donor and acceptor fluorescent proteins instead of ECFP and 
EYFP, as their optical properties are better for this application. Acceptor-centric 
measurements of FRET were obtained with the 33-FRET algorithm7,14, which expresses 
the effective FRET efficiency (EEFF) and FRET ratio (FR) as: 
 𝐸𝐸EFF = 𝐸𝐸 × 𝐴𝐴b = (𝐹𝐹𝐹𝐹 − 1)[𝜀𝜀ven(440𝑛𝑛𝑛𝑛) 𝜀𝜀cer(440𝑛𝑛𝑛𝑛⁄ )]                      
where 𝐸𝐸 =  𝑘𝑘T/(𝑘𝑘T + 𝑘𝑘D) is the FRET efficiency of a donor-acceptor pair, 𝐴𝐴b is 
the fraction of acceptor molecules bound by a donor. 𝜀𝜀ven(440𝑛𝑛𝑛𝑛)/𝜀𝜀cer (440𝑛𝑛𝑛𝑛) is the 
approximate molar extinction coefficients of Cerulean and Venus, which was measured as 
0.08 on our setup.  
Flow-cytometer-based FRET optical imaging. FRET two-hybrid experiments 





described49. Cells were trypsinized and resuspended in Tyrode’s solution before loading 
onto the flow cytometer. The previously described algorithm7,14 was used to calculate 
acceptor-centric measures. In total, signals from 1,000-10,000 cells were recorded, 
however only 30-50 randomly selected cells were displayed in order to improve clarity of 
the figure.  
Mass spectroscopy. Double Histidine (His8) tagged Cerulean-ICDI1.4 peptides 
were co-transfected with PKA holoenzyme in HEK293T cells. Cells were incubated in 50 
µM forskolin in a 37°C incubator for 1 hour before collecting with a lysis buffer, 
containing (in mM): KCl, 20; K-gluconate, 120; MgCl2, 2; EGTA, 0.2; HEPES (pH 7.4); 
Na2-ATP; 2; DTT, 10; cAMP, 0.1. Protease inhibitor cocktail (Roche, complete, EGTA-
free), phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich) were added into the lysis 
buffer according to the standard protocol. His-tagged Cerulean-ICDI1.4 peptides were 
purified by Ni-NTA agarose (QIAGEN) and verified by SDS-PAGE using mini-
PROTEAN precast gel (Bio-Rad). The band containing the ICDI1.4 peptide (Figure 30A) 
was cut from the gel then sent to the Johns Hopkins Mass Spectroscopy and Proteomics 
Facility, where the peptides were in-gel proteolyzed with trypsin and analyzed on nano-
LC ESI/MS/MS Orbi-trap Velos in FTFT mode. Tandem MS2 mass spectra were 
processed by Proteome Discoverer (v1.4 Thermo Fisher Scientific) in three ways, using 3 
Nodes: common, Xtract (spectra are extracted, charge state deconvoluted, and deisotoped 
using Xtract option), MS2 Processor. The tandem mass spectra were searched against the 
RefSeq2014 Human database filtered at a 1% FDR using PEAKS 7.0 (Bioinformatics 





phosphorylation were searched for with a precursor ion tolerance of 10 ppm and a 
fragment ion tolerance of 0.02 daltons.  
Two peptides (peptide 1: GSADSLVEAVLISEGLGLFAR and peptide 2: 
LTLDEMDNAASDLLAQGTSSLYSDEESILSR) from CaV1.4 were identified, which 
covered 52% of the total 100 amino acids in ICDI1.4 (Figure 29) and 11 of the 14 
potential phosphorylation sites in this region. Three potential sites, T1872, S1874, and 
S1877, were not covered due to the limitation of trypsin, but they are not in the core 
region for IQ interaction89. Peptide 1 was identified nine times, among which it carried a 
phosphate group six times. The peaks from double and triple charged peptides detected in 
the first MS showed a molecular weight that was 79.97 daltons higher than that expected 
without a phosphate group, verifying phosphorylation. The data predicted that either 
S1883 or S1886 could be the site of phosphorylation. However the existence of b4, b4(-
98) and y17 in the spectra in (Figure 31A and Figure 30B) strongly suggested that the 
phosphorylation site is S1883.  In addition, pkaPS predictions and mutagenesis (Figure 
31D, E and Figure 29C, D) strongly support that the PKA phosphorylation site is S1883. 
Peptide 2 was identified twelve times, and carried a phosphate group at S1942 in only 
one trial. This potential phosphorylation site, however, did not have any effect on the 







The interaction between IQ and ICDI domains regulated by PKA in aGPVMs 
The ICDI domain in certain L-type Ca2+ channels is known to bind to the IQ 
region of the channel, displacing CaM and reducing the CDI and PO of the channel6,8. 
Given the functional importance of this IQ/ICDI binding, we sought to assess if this 
interaction might be modulated by PKA phosphorylation. To this end, we utilized a live-
cell FRET two hybrid assay, pairing Venus-tagged IQ domains against Cerulean-tagged 
ICDI domains from various L-type Ca2+ channels. Although not required for CaM 
binding40, the downstream A-region8,90 was included within our IQ construct (IQ-A) as it 
contributes to the binding between the IQ and ICDI domains (Chapter 1)89. Cognizant 
that full-bore PKA signaling is best conserved within certain native rather than model 
cells79,91, we performed the FRET assays in aGPVMs, which are renowned for their 
strong PKA signaling. The FRET pairs were transduced into aGPVMs via adenoviral 
vectors, allowing rapid and tunable expression within acute (one day) myocytes48 (Figure 
16A, B). 
There are three L-type calcium channels of interest, CaV1.2, CaV1.3 and CaV1.4, 
and FRET binding curves were constructed for the mix and match of their IQ-A and ICDI 
peptides (Figure 16C).  We began by pairing the IQ-A module from the CaV1.3 channel 
(IQ-A1.3) with the ICDI domain from CaV1.4 (ICDI1.4) as the functional consequence of 
this interaction has been demonstrated in previous studies8 and Chapter 1. Indeed, FRET 
two-hybrid measurements in aGPVMs yielded a robust binding curve (Figure 16C, gray) 





such, this model interaction was used to compare with other interactions. Interestingly, all 
three IQ-A peptides bind well with ICDI1.4, and all three ICDI peptides has relatively 
high affinity to IQ1.3. The rest of the mix and match pairs bind with lower affinity (Figure 
16C).  
Next, we tested whether PKA can regulation these interactions. Remarkably, the 
interaction between of IQ-A1.3 and ICDI1.4 is largely disrupted when PKA is activated by 
the addition of 0.5 µM isoproterenol (Figure 17A, red). Moreover, this PKA effect can be 
elicited as a dynamic response within an exemplar myocyte (Figure 17B, C). The 
application of 0.5 µM isoproterenol decreases the FRET ratio exponentially indicating a 
disruption in binding. Of note, the individual CFP and FRET signals have corresponding 
changes, while the YFP signal remains relatively stable, indicating a genuine FRET 
response rather than an artifact due to isoproterenol acting directly on the fluorophores. 
Importantly, the decrease in FRET ratio (FR) can be reversed either by washing off 
isoproterenol (Figure 17A) or by inhibiting PKA via addition of either the wide-spectrum 
kinase inhibitor staurosporine (Figure 17B) or the PKA inhibitor H89 (Figure 17C), 
demonstrating a PKA specific effect. Thus the binding of IQ-A1.3 and ICDI1.4 can be 
dynamically modulated by PKA phosphorylation in a reversible manner. 
This disruption of binding by PKA demonstrates a likely phosphorylation site on 
one of these two channel segments; however the interaction probed thus far has been 
between the ICDI and IQ domains of different L-type Ca2+ channels which may be 
unlikely to interact in a physiological setting92. We therefore probed for similar 





Gratifyingly, a FRET two-hybrid assay revealed a strong interaction between the IQ-A1.4 
and ICDI1.4 peptides (Figure 18A, gray), which was diminished by PKA activation 
(Figure 18A, red and B) and reversed by the PKA inhibitor H89 (Figure 18B). In 
contrast, when both IQ and ICDI domains were from either CaV1.2 or CaV1.3, activating 
PKA had no effect on the binding affinity between the two domains (Figure 19). Thus 
CaV1.4 channels may represent the relevant native context for this PKA modulation. 
Moreover, the PKA modulation of ICDI1.4 with multiple L-type Ca2+ channel IQ-A 
regions (Figure 18, 19) points to the likelihood that the phosphorylation site responsible 
for this effect lies within the ICDI region of the CaV1.4 channel. 
The interaction between IQ and ICDI domains regulated by PKA in HEK293 
The discovery that the binding between L-type Ca2+ channel IQ domains and 
ICDI1.4 can be attenuated by PKA activation in aGPVMs is compelling, however the 
functional implications of this modulation could best be probed in a heterologous 
expression system where full control of channel and interacting partners is possible14. 
Unfortunately, full replication of PKA modulation of L-type channels is not always 
straightforward in recombinant systems83. We therefore sought to reconstruct the PKA 
regulation of IQ binding with ICDI in HEK293 cells. As the IQ-A1.3/ICDI1.4 interaction is 
robustly modulated (Figure 17), we first attempted to replicate the PKA modulation of 
this interaction through the application of forskolin. However, the effect of forskolin on 
this binding interaction was minimal (Figure 21A). Reasoning that HEK293 cells may 
have decreased endogenous PKA signaling as compared to aGPVMs, we overexpressed 





IQ-A1.3 with ICDI1.4 was indeed reduced (Figure 20B). Given this success, we probed the 
PKA effect on IQ/ICDI interactions within a single channel subtype. Consistent with the 
data from aGPVMs, the interaction between IQ-A1.4 and ICDI1.4 was modulated by PKA 
(Figure 20C), while the interaction between peptides derived from CaV1.2 or CaV1.3 
were unaffected (Figure 20D, E). Thus we have established PKA specific modulation of 
the IQ/ICDI interaction within CaV1.4 Ca2+ channels, as well as across CaV1.3 and 1.2 
channels, within a heterologous system. 
Utilizing this expression system, the functional consequence of this PKA 
modulation could now be assessed. Given the ability of ICDI to compete with CaM for 
the channel IQ region, we tested whether disruption of IQ/ICDI binding might affect 
channel CDI. We utilized the chimeric CaV1.3S/1.4DCT channel6,8 (CaV1.3 with the DCT 
replaced by that of CaV1.4) as introduction of ICDI1.4 in this channel is known to ablate 
the CDI of wild-type CaV1.38 as seen by the minimal difference in the decay of Ca2+ (red) 
versus Ba2+ (black) current (Figure 20F). However, if PKAc is now overexpressed in 
these cells, CDI is restored, as demonstrated by the stronger decay in the Ca2+ (red) 
current as compared to the Ba2+ (black) current (Figure 20G). Population data plotting 
the ratio of current remaining after 100 ms (r100) demonstrates a hallmark U-shaped 
dependence on voltage, further corroborating a full restoration of CDI in the chimeric 
channel due to PKA activity. This restoration of CDI is indicative of a shift in the binding 
of the IQ region from ICDI1.4 back to CaM in the phosphorylated state. Thus, PKA 
regulation of the IQ/ICDI interaction is capable of significantly altering the inactivation 





Creating a robust and controllable PKA system in HEK293 cells 
While the dramatic effect on CDI is compelling, such constitutive activation of 
PKA could produce multiple long-term effects including alterations in gene expression93. 
Consequently, dynamic modulation of PKA activity is necessary to fully test the effect of 
PKA induced ICDI phosphorylation.  Although PKA regulation of the IQ1.3/ICDI1.4 
interaction was easily observed in aGPVMs (Figure 17), the same regulation was absent 
in HEK293 cells (Figure 21), which implies that endogenous PKA may not be sufficient 
in these cells for our experiments. It may therefore be necessary to overexpress PKA in 
order to achieve a functional model system.  
As a tightly regulated and highly sensitive system, the regulatory subunits of PKA 
usually slightly outnumber the catalytic subunits at endogenous expression levels, so that 
most cells has minimal PKA activity at baseline (Figure 22B). The delicately balanced 
expression of regulatory and catalytic subunits in native systems cannot be easily 
achieved by standard heterologous expression, as co-transfection of both subunits results 
in mixed basal PKA activity. Indeed, when we co-expressed both subunits of PKA with 
the CaV1.3S/1.4DCT chimeric channels, we observed variable CDI (data not shown). To 
mimic the endogenous expression of native systems and guarantee low basal PKA 
activity, the overexpressed regulatory subunits have to slightly outnumber the 
overexpressed catalytic subunit. To achieve this, we linked the catalytic and regulatory 
subunits by a viral-based 2A sequence from porcine tescho virus (P2A) optimized and 
characterized in a previous study94. The P2A sequence causes a self-hydrolysis reaction at 





the linked subunits. A small amount of extra regulatory subunit (1 µg per 4 µg 
holoenzyme) was co-expressed with this P2A construct in order to ensure that PKA 
activity remained low at basal levels in every cell.  
To test PKA holoenzyme in indeed overexpressed without increasing basal PKA 
activity, we used the FRET-based PKA activity sensor AKAR495, because it is a very 
sensitive PKA sensor that can detect endogenous PKA activity in HEK293 cells (Figure 
22A). We first expressed AKAR4 in HEK293 cells, and measured the FRET efficiency 
(Eeff) of each cell by flow cytometer. At this endogenous PKA expression level, most cells 
exhibited low PKA activity, as illustrated by the low Eeff of AKAR4, while a small 
percentage of cells showed high basal PKA activity (Figure 22B). When PKA 
holoenzyme was also expressed as described above, every cell had minimal basal PKA 
activity, indicated by the low Eeff of AKAR4 (Figure 22C). In addition, when the cAMP 
level was elevated by adding 50µM forskolin, PKA activity was saturated in all cells, 
indicated by the high Eeff of AKAR4 (Figure 22D). 
With the overexpression of PKA holoenzyme, the addition of 50 µM forskolin 
was now sufficient to rapidly decrease the FRET interaction between IQ-A1.3 and ICDI1.4 
peptides within HEK293 cells (Figure 21B). Thus the PKA holoenzyme was 
overexpressed this way in the subsequent experiments in HEK293 cells.   
Controllable PKA regulation of chimeric L-type channels in HEK293 cells 
Having achieved robust forskolin-dependent PKA modulation of binding between 
L-type channel fragments in HEK293 cells, we next sought to test the effect of this 





CaV1.3S/1.4DCT channel, co-expressed with the PKA holoenzyme, as our model system. In 
order to minimize the perturbation of the cells, they were incubated with 50 µM forskolin 
for 30 minutes prior to whole-cell patch clamp recording.  Indeed, forskolin incubation at 
room temperature restored a small but significant amount of CDI as compared to without 
forskolin (Figure 22A, B). However, the level of restoration is much less comparing to 
constitutive PKAc overexpression (Figure 20G), which indicates CDI restoration might 
takes longer than 30 minutes. We know that disruption of binding between IQ-A1.3 and 
ICDI1.4 peptides responds to PKA activation (Figure 21C) within a few minutes, then 
why CDI restoration of the chimeric channel develops much slower? On one hand, the 
effective local concentration of IQ domain near ICDI is higher in the holochannel 
configuration comparing to in the peptide form, as the two domains link together in the 
channel. Accordingly, it is harder for PKAc to approach and phosphorylate ICDI domain. 
On the other hand, slow CaM recruitment to the channel after disruption of the binding 
between IQ and ICDI interaction might also contribute to the slow response time. This 
hypothesis is supported by the slow time course observed when CaM was recruited to the 
same channel via rapamycin6. To speed up CDI restoration, we increased incubation 
temperature, and indeed observed larger amount of CDI restoration after incubation in 
forskolin at 30°C or 37°C for 30 minutes (Figure 21D, E). While the extent of CDI 
varied somewhat from cell to cell, a significant right shift in the cumulative distribution 
of r100 demonstrates a clear effect of forskolin on CDI (Figure 21).  This sharp 
temperature dependence of phosphorylation kinetics explains the importance of body 





reactions in a complex system, even though the interaction and phosphorylation reaction 
themselves are not expected to be very sensitive to small temperature fluctuation.   
The fact that PKA activation can restore channel CDI confirmed that PKA 
regulation of interaction between IQ and ICDI domains has direct impact to channel 
function. However, based on our hypothesis, phosphorylation of ICDI by PKA should 
also increase the channel PO. To observe the concurrent increase in PO and CDI, we 
added 50µM forskolin while recording whole-cell Ca2+ currents at a bath temperature of 
30⁰C. To avoid the loss of either PKA or CaM from the cytosol due to dialysis, we co-
expressed AKAP79 to anchor PKA to the membrane, and tethered CaM to the β2a subunit 
of the channel (Figure 24A). A 20 mV depolarizing step was applied for 150 ms every 30 
seconds, allowing resolution of the current amplitude and CDI over the time course of 
forskolin wash-on (Figure 24B). The addition of forskolin caused a steady increase in 
peak current amplitude (green), reaching a level several fold larger than the pre-forskolin 
current. At the same time, the steady state current remaining after 100 ms was remarkably 
stable (gray), resulting in an increase in CDI. This outcome is consistent with a previous 
study whereby CaM was enriched near the CaV1.3S/1.4DCT channel via rapamycin-induced 
dimerization6, further substantiating the hypothesis that PKA activation results in 
increased CaM binding to the channel IQ due to a reduction in the affinity of IQ1.3 with 
ICDI1.4. 
ICDI1.4 can act as a modular phospho-switch for CaV1.2  
Beyond CaV1.3, ICDI1.4 was also able to bind to IQ-A1.2 in a PKA sensitive 





synthetic phospho-switch for CaV1.2 Ca2+ channels, able to be plugged into a system 
simply by co-expression as a cytosolic peptide. Such synthetic modulation of the CaV1.2 
channel may be of particular interest as these channels are known to undergo a large 
increase in current amplitude in response to PKA activation in myocytes, however this 
effect is exceedingly difficult to replicate in recombinant systems83. We therefore sought 
to utilize ICDI1.4 to generate PKA modulation of CaV1.2 channels in HEK293 cells. In 
order to maintain the properties of cardiac CaV1.2 channels as much as possible in our 
recombinant system, we co-expressed ICDI1.4 as a peptide along with the full-length 
cardiac CaV1.2 channel, and utilized the β1b Ca2+ channel subunit which more closely 
recapitulates the inactivation profile found in native cardiac myocytes91 (Figure 25A). As 
before, CaM was linked to the beta subunit, and AKAP was co-expressed so as to reduce 
dialysis of the key elements. Under these conditions, application of 50 µM forskolin 
largely increased the peak amplitude (Figure 25B), similar to the native PKA up-
regulation of cardiac CaV1.2 channels (Figure 26). In addition, an increase in CDI was 
seen even in the presence of significant voltage dependent inactivation due to the use of 
the β1b subunit96. Thus, the effect of ICDI1.4 on channel regulation demonstrated in the 
chimeric CaV1.3S/1.4DCT channel appears to be generalizable to other L-type Ca2+ channels. 
Moreover, ICDI1.4 need not be covalently attached to the channel, but rather is capable of 
acting as a diffusible CDI/PO switch, which can be turned off by PKA phosphorylation. 
PKA activation regulates full-length CaV1.4 channels 
It is now clear that ICDI1.4 can serve as a synthetic phospho-switch for CaV1.2 





demonstrated. Given that the FRET interaction of ICDI1.4 with IQ-A1.4 is dramatically 
reduced by PKA activation (Figure 18 and Figure 20c), our data predicts that native 
CaV1.4 channels are likely modulated by PKA. To elucidate this effect, we co-expressed 
full-length, wild-type CaV1.4 along with PKA (Figure 27A) as previously done for the 
chimeric channel (Figure 23A). Indeed, these channels exhibited no CDI at baseline, 
however following a 60-minute incubation with forskolin, considerable CDI was elicited 
(Figure 27B). In addition, co-expression of wild-type CaV1.4 with β2a-CaM, AKAP and 
PKA allowed for resolution of a dynamic response to PKA (Figure 27C). In response to 
the addition of 50 µM forskolin, both the peak current amplitude and CDI increased 
significantly (Figure 27D). Thus wild-type CaV1.4 channels employ a mechanism for 
CDI and PO modulation whereby ICDI1.4 binds to the IQ region at baseline, and is 
displaced by CaM following the phosphorylation of ICDI1.4 by PKA. With CaM residing 
on the IQ region of the channel, the channel PO is increased and CDI is enabled6. 
Lack of ICDI mediated PKA regulation of CaV1.3 and CaV1.2  
The ICDI domain of CaV1.4 exhibits significant sequence homology to the ICDI 
domain of other L-type Ca2+ channels (Figure 6).  In fact, the ability of ICDI to compete 
with CaM for binding to the IQ domain of the channel has been demonstrated for both 
CaV1.3 and CaV1.2 channels.  However, we utilized the FRET two-hybrid binding assay 
to probe for interactions between the IQ and ICDI regions of CaV1.3 and 1.2 channels and 
demonstrated that they are not regulated by PKA activation in either aGPVMs (Figure 
19C, D, G, H) or HEK293 cells (Figure 20D, E).  Thus, we expected full-length CaV1.2 





enhanced PKA expression system used for CaV1.4 channels (Figure 27C), forskolin 
failed to induce a change in CDI or current amplitude of CaV1.3 channels in HEK 293 
cells (Figure 28A, B). Similarly for CaV1.2 channels, no modulation of CDI or current 
amplitude can be seen in the heterologous expression system (Figure 28C, D). Thus 
despite the sequence similarity of IQ and ICDI domains across CaV1.2, 1.3 and 1.4, the 
PKA regulation is unique in CaV1.4. 
Identification of the PKA phosphorylation site within CaV1.4  
Thus far we have demonstrated that elevated PKA activity correlates with 
increased peak current amplitude and CDI of L-type Ca2+ channels in the presence of 
ICDI1.4. We hypothesized that this effect is due to direct phosphorylation of ICDI1.4, 
however an indirect effect due to phosphorylation of an unknown ICDI interacting 
element could produce a similar result. As a first step towards identifying the site, we 
utilized the bioinformatics tool pkaPS97 to predict potential PKA phosphorylation sites 
within ICDI1.4. From this prediction algorithm, S1883 appeared to be the most likely site 
(Figure 29A).  
To confirm this result, we employed mass spectroscopy to identify 
phosphorylation sites within ICDI1.4. In order to induce phosphorylation, a histidine-
tagged ICDI1.4 peptide was co-expressed with the PKA holoenzyme in HEK293 cells and 
subjected to one hour of forskolin treatment. The result of mass spectroscopy on this 
peptide revealed that S1883 is indeed phosphorylated (Figure 31A and Figure 30), 






Having established S1883 as a potential PKA phosphorylation site, we sought to 
determine whether this site is responsible for the functional modulation of the channel. To 
determine if the site is required for the PKA modulation of binding between L-type 
channel IQ regions and ICDI1.4, we utilized a novel flow-cytometer based high-
throughput platform for live-cell FRET two-hybrid binding assay49. As seen by traditional 
FRET two-hybrid binding (Figure 20B), overexpression of PKAc reduced the binding 
affinity of Venus-tagged IQ-A1.3 and Cerulean-tagged ICDI1.4 peptides (Figure 31B, C). 
However, when S1883 within ICDI1.4 was mutated to alanine, the PKA modulation of the 
interaction was abolished (Figure 31D). In contrast, if S1886 was mutated to alanine, 
PKA regulation was preserved (Figure 31E). Finally, we probed the functional effect of 
the S1883A mutation via whole cell patch clamp recording. The CaV1.3S/1.4DCT chimeric 
channel was utilized for these experiments as it expresses well and exhibits robust and 
consistent PKA modulation. Mutation of S1883 to alanine had no effect on channel 
properties in the absence of PKA (Figure 31F), however overexpression of PKAc failed 
to alter CDI (Figure 31G), confirming that S1883 is a novel and functional PKA 
phosphorylation site within the CaV1.4 ICDI domain. 
 
Discussion 
PKA phosphorylation of ICDI1.4 has significant, previously unreported, effects on 
wild-type CaV1.4 channels. Such novel PKA regulation may have important 
physiological consequences. CaV1.4 is the main L-type Ca2+ channel in the retina92. 





makes detailed study of their PKA modulation challenging, the creation of a robust PKA 
system in HEK293 cells has enabled new mechanistic insight. We now know that PKA 
phosphorylation of ICDI1.4 disrupts its IQ binding, allowing CaM to bind the IQ region, 
thus increasing channel PO and CDI. Such a mechanism may well be at play in the retina. 
Ca2+ currents within photoreceptors exhibit a modest amount of CDI, which has been 
attributed to a mixture of CaV1.4 channel splice variants86,98.  Here, we have 
demonstrated that even the long splice variant, containing ICDI1.4, is capable of 
supporting CDI under elevated PKA activation and likely contributes to the CDI seen in 
these cells. Moreover, ICDI1.4 is highly expressed in retina and PKA activity retina is 
robustly regulated by dopamine99.  As the dopamine fluctuations in the retina with 
circadian rhythmicity, they exhibit oscillations with periods lasting for many hours100,101 
rationalizing the relatively slow kinetics of CaV1.4 regulation by PKA (Figure 27D). 
Thus, PKA regulation of CaV1.4 could modulate visual sensitivity during the day-night 
cycle. In fact, channelopathic mutations in CaV1.4 which cause premature truncation 
before the ICDI domain, result in congenital stationary night blindness9,13, demonstrating 
the importance of this module in low light adaptation.  
Beyond CaV1.4 channels, ICDI1.4 was able to endow chimeric CaV1.3 and 1.2 
channels with robust PKA modulation, demonstrating a generalizable mechanism for 
regulation of L-type channel CDI and PO.  Moreover, ICDI1.4 was also able to act as a 
synthetic phospho-switch when co-expressed as a separate peptide with CaV1.2 channels. 
This synthetic PKA modulation of channel opening and CDI could be a valuable tool to 





transduced into native cells. Moreover, co-expression of this peptide at basal PKA levels 
mimics the properties of certain long Ca2+ channel splice variants6, while elevation of 
PKA activity reverts the phenotype of these channels to that of a short splice variant. As 
such, this tool could aid in understanding the functional effects of alterations in splice 
variant expression in different cell types.  
Such a synthetic phospho-switch may have added value beyond that of a novel 
tool for regulating L-type Ca2+ channels. It may shed light on the mechanism underlying 
native PKA regulation of L-type Ca2+ channels. In particular, the regulation of cardiac 
CaV1.2 channels by PKA is a critical feature of the fight-or-flight response, but the full 
mechanistic pathway underlying this regulation remains under debate24,43. While PKA 
activation readily increases CaV1.2 current by several fold in adult cardiomyocytes, such 
large PKA upregulation is not often observed in heterologous systems such as HEK293 
cells83, even in the presence of exogenous PKA holoenzymes (Figure 28D). It appears, 
then, that there must be a critical element in myocytes which is lacking in recombinant 
systems24,91. Given the ability of ICDI1.4 to modulate CaV1.2 channel PO in a 
phosphorylation dependent manner, we wonder if the missing element in myocytes may 
employ a similar strategy. Thus, searching for proteins capable of binding channel IQ 
domains may prove a useful approach.  
To ensure the presence of all key elements of the PKA pathway within our 
binding assay, we implemented quantitative live-cell FRET two-hybrid binding in acutely 
isolated aGPVMs.  This system enabled us to probe the PKA modulation of IQ/ICDI1.4 





21A). This failure of forskolin to modulate the IQ/ICDI1.4 interactions in HEK293 cells at 
baseline points to an important limitation of these cells. While these cells have proven 
quite useful for studying many types of PKA modulation including HERG50, KV1.152 and 
nicotinic receptors45, they appear less ideal for studying the modulation of L-type Ca2+ 
channels. It therefore seems likely that these phosphorylation targets have different 
thresholds for PKA modulation, and model systems in which PKA is sufficient for one 
application may not be suitable for all target proteins.  
Overall, we have demonstrated that the repertoire of PKA regulation of L-type 
Ca2+ channels extends to CaV1.4 channels. The identification of the phosphorylation site 
within the CaV1.4 ICDI domain fits well with a mechanism in which PKA mediated 
phosphorylation alters the binding affinity between the IQ and ICDI domains of CaV1.4, 
thus tuning the extent of CDI and channel PO via competitive displacement of CaM. 
Given the distribution of CaV1.4 channels, this modulation might play an important role 
in the visual system and in tuning the circadian rhythm, and may represent a general 
mechanism by which various L-type channels could be modulated by currently 






























Figure 16. FRET two-hybrid assays of IQ-A/ICDI interactions in aGPVMs.   
(A) FRET partners are Venus- IQ-A peptide and Cerulean-ICDI peptides from L-type 
calcium channels. (B) Adenovirus incorporating FRET binding partners were used to infect 
aGPVMs. (C) The IQ-A peptides and ICDI peptides from CaV1.2, CaV1.3 and CaV1.4 were 
mixed and matched to generate nine binding pairs. Binding curves were constructed for 
each of the nine binding paris by FRET two-hybrid in aGPVMs. Each filled circle 
represents recording from a single cell. The binding curve of Venus-IQ-A from CaV1.3 and 





















 Figure 17. PKA regulation of IQ1.3 and ICDI1.4 interactions in aGPMVs. 
 (A) FRET binding curve for Venus-IQ-A1.3 paired with Cerulean-ICDI1.4 (gray). 0.5 µM 
isoproterenol (red) decreases the relative binding affinity. Each point indicates a single cell. 
The control binding curve is replicated as the gray curve in the lower panel here and 
throughout. FR, FRET ratio; Dfree, relative concentration of unbound Cerulean-tagged 
ICDI1.4. (B) Kinetics of normalized fluorescent signals from YFP channel (SYFP), CFP 
channel (SCFP), FRET channel (SFRET) and calculated FR from an exemplar aGPVM 
expressing Venus-IQ-A1.3 and Cerulean-ICDI1.4, with 0.5 µM isoproterenol and 0.5 µM 
staurosporine added as indicated. Fluorescent signals were normalized to baseline here and 
throughout. (C) Kinetics of normalized fluorescent signals and FR from an exemplar 
aGPVM expressing Venus-IQ-A1.3 and Cerulean-ICDI1.4, with 0.5 µM isoproterenol and 
10 µM H89 added as indicated. For this data set, a movement artifact was noted in the raw 

















Figure 18. PKA regulation of IQ1.4 and ICDI1.4 interactions in aGPMVs. 
 (A) FRET binding curve for Venus-IQ-A1.4 paired with Cerulean-ICDI1.4 (gray). 0.5 µM 
isoproterenol (red) decreases the relative binding affinity. (B) Kinetics of normalized 
fluorescent signals from YFP channel (SYFP), CFP channel (SCFP), FRET channel (SFRET) 
and calculated FR from an exemplar aGPVM expressing Venus-IQ-A1.4 and Cerulean-
ICDI1.4, with 0.5 µM Isoproterenol and 10 µM H89 added as indicated. Fluorescent signals 





























Figure 19. PKA regulation of other IQ and ICDI interactions in aGPMVs.  
(A) FRET binding assays between Venus-IQ-A1.2 and Cerulean-ICDI1.2 peptides, without 
(gray) or with (red) application of isoproterenol (iso). The gray curve in the middle panel 
is replicated in the lower panel, overlapping the red curve.  (B) Kinetics of normalized 
fluorescent signals from the YFP channel (SYFP), CFP channel (SCFP), FRET channel 
(SFRET) and calculated FRET ratio (FR) from an exemplar aGPVM expressing Venus-IQ-
A1.2 and Cerulean-ICDI1.2. Isoproterenol was applied as indicated, without any effect. 
Fluorescent signals were normalized to baseline. (C) FRET binding assays between 
Venus-IQ-A1.3 and Cerulean-ICDI1.3 peptides, without (gray) or with (red) isoproterenol. 
(D) Lack of response to isoproterenol by an exemplar aGPVM expressing Venus-IQ-A1.3 
and Cerulean-ICDI1.3 peptides. (E) FRET binding curve indicating robust interaction 
between Venus-IQ-A1.2 and Cerulean-ICDI1.4 peptides. (F) Isoproterenol causes a 
significant decrease in FR within an exemplar aGPVM expressing Venus-IQ-A1.2 and 
Cerulean-ICDI1.4 peptides. (G) FRET binding assay between Venus-IQ-A1.3 and 
Cerulean-ICDI1.2 peptides. (H) Lack of response to isoproterenol in an exemplar aGPVM 

































Figure 20. The catalytic subunit of PKA regulates IQ binding to ICDI1.4 in HEK293 
cells.  
(A) FRET binding assays (B-E) between Venus-IQ-A and Cerulean-ICDI demonstrating 
the effect of PKAc overexpression. (B, C) PKAc reduces the binding between IQ-A1.3 and 
ICDI1.4 (B) and between IQ-A1.4 and ICDI1.4 (C). (D, E) PKAc does not change binding 
between IQ-A1.2 and ICDI1.2 (D) or IQ-A1.3 and ICDI1.3 (E). (F) Cartoon of the chimeric 
channel CaV1.3S/1.4DCT made by attaching the DCT of CaV1.4 (including ICDI, red) to a 
truncated CaV1.3 (left). Exemplar of whole-cell current (middle) illustrates a lack of CDI, 
as seen by the minimal difference in decay of Ca2+ (red) versus Ba2+ (black) current. 
Vertical scale bar pertains to Ca2+ current; Ba2+ current scaled downwards ~3× to facilitate 
comparison of decay kinetics, here and throughout. Population data (right) confirmations 
minimal CDI of this chimera. The fraction of peak current remaining after 100-ms (r100) is 
plotted versus step voltage (V), for Ba2+ (black) and Ca2+ (red) currents (mean ± SEM). (G) 
Overexpression of PKAc (left) restored CDI of this chimeric channel, showing a strong 
decay of Ca2+ current (red) compared to Ba2+ current (black). The classic U-shaped voltage 
























Figure 21. Forskolin regulation of the interaction of IQ1.3 and ICDI1.4 in HEK293.  
 (A) Time course of normalized fluorescent signals from YFP channel (SYFP), CFP 
channel (SCFP), FRET channel (SFRET) and calculated FRET ratio (FR) from an exemplar 
HEK293 cell expressing Venus-IQ-A1.3 and Cerulean-ICDI1.4 peptides. (B) Time course 
of normalized fluorescent signals and calculated FR from an exemplar HEK293 cells 

















Figure 22. Co-expressing PKA holoenzyme ensures robust and controllable PKA 
activity.  
(A) An exemplar recording demonstrating the kinetics of the AKAR response in HEK 293 
cells.  YFP signal: yellow; CFP signal: cyan; FRET signal: green; FR: red. (B) FRET 
efficiency (Eeff) measured for HEK293 cells expressing the PKA sensor AKAR44. Each 
point indicates a single cell. The blue line represents low PKA activity, and the red line 
indicates high PKA activity. (C)  Eeff measured for HEK293 cells expressing AKAR4 and 
PKA holoenzyme, without forskolin treatment. (D) Eeff measured for fosrkolin treated 
HEK293 cells expressing AKAR4 and PKA holoenzyme, recorded after incubation in 































Figure 23. Temperature dependence of PKA modulation of CaV1.3S/1.4DCT  
(A) Schematic of HEK293 cells co-expressing CaV1.3S/1.4DCT channels, PKA holoenzyme 
(catalytic subunit, C and regulatory subunit, R, linked by a P2A sequence at the DNA 
level). (B) Minimal CDI at basal PKA levels. (Left) Exemplar of whole-cell current 
illustrates a lack of CDI, as seen by the minimal difference in decay of Ca2+ (red) versus 
Ba2+ (black) currents. Vertical scale bar pertains to Ca2+ current; Ba2+ current scaled 
downwards ~3× to facilitate comparison of decay kinetics, here and throughout. (Middle) 
Population data confirmations minimal CDI. The fraction of peak current remaining after 
100-ms (r100) is plotted versus step voltage (V), for Ba2+ (black) and Ca2+ (red) currents 
(mean ± SEM). (right) The tight cumulative distribution of r100 across all cells also 
indicates minimal CDI. (C) CDI emerges after incubation in 50 µM forskolin at 23°C for 
30 minutes. (D) Incubation with 50 µM forskolin for 30 min at 30°C increases the extent 
of CDI. (E) Incubation with 50 µM forskolin for 30 min at 37°C further increases the 




























Figure 24. Dynamic PKA regulation of chimeric CaV1.3S/1.4DCT channels in HEK293 
cells.  
(A) Schematic of HEK293 cells co-expressing chimeric CaV1.3S/1.4DCT and PKA 
holoenzyme (catalytic subunit, C and regulatory subunit, R, linked by a P2A sequence at 
the DNA level), AKAP79 and β2a tethered CaM which allowed longer whole cell patching 
without loss of PKA or CaM. (B) Time course of normalized peak current (green) and 
steady state current (gray) in response to the addition of 50 µM forskolin, evoked every 30 
seconds by depolarizations to 20 mV (top). The corresponding increase in CDI (middle) 
from whole-cell Ca2+ currents. Currents were normalized to baseline. CDI was measured 
as 1 - r100. All error bars indicate +/- SEM (n = 6 cells). Corresponding current waveforms 



























Figure 25. Synthetic PKA regulation of CaV1.2 in HEK293 cells.  
(A) Schematic of full-length CaV1.2 channel, PKA honoenzyme (R and C) and ICDI1.4 
peptide, along with β1b tethered CaM and AKAP79. (B) Time course of the normalized 
peak current (top) and CDI (middle), from whole-cell Ca2+ currents, evoked every 30 
seconds by depolarizations to 20 mV. Currents were normalized to baseline. CDI measured 
as 1 - r100. All error bars indicate +/- SEM (n = 6 cells). Corresponding current waveforms 













Figure 26. Comparison of the native and synthetic regulation of CaV1.2.  
(A) Ca2+ current elicited by step depolarization from -80mV to 20mV from an adult guinea 
pig ventricular myocyte (aGPVM), before (black) and after (red) application of 0.5 µM 
isoproterenol. (B) Ca2+ current from a HEK293 cell expressing CaV1.2, ICDI1.4 peptide and 
PKA holoenzyme (Figure 25A), elicited by step depolarization from -80mV to 20mV, 

























Figure 27. PKA regulation of full-length wild-type CaV1.4 channels in HEK293 cells.  
(A) Schematic of wild-type CaV1.4 channels with PKA holoenzyme. (B) No CDI at 
baseline (left), however incubation in 50 µM forskolin induces clear CDI (right). Format 
as in Figure 23B, D. (C) Schematic of CaV1.4 and PKA holoenzyme, AKAP79 and β2a 
tethered CaM. (D) Time courses for normalized peak current (top) and CDI (middle) from 
whole-cell Ca2+ currents in response to 50 µM forskolin. Currents are evoked every 30 
seconds by 20 mV depolarizations. Currents were normalized to baseline and CDI was 
measured as 1 - r100. Error bars indicated +/- SEM (n = 4 cells). Corresponding current 
























Figure 28. PKA does not regulate the IQ and ICDI interaction in CaV1.3 and 
CaV1.2.  
(A) Schematic of co-expression of CaV1.3 with PKA holoenzyme, AKAP79 and β2a 
tethered CaM which allowed longer whole cell patching without loss of PKA or CaM. 
(B) Time course of normalized peak current (top) and CDI (bottom) in response to the 
addition of 50 µM forskolin (n = 5 cells). Corresponding current waveforms are 
displayed below.  (C) Schematic of co-expression of CaV1.2 with PKA holoenzyme, 
AKAP79 and β1b tethered CaM which allowed longer whole cell patching without loss of 
PKA or CaM. (D) Time course of normalized peak current (top) and CDI (bottom) in 
response to the addition of 50 µM forskolin (n = 4 cells). Corresponding current 












Figure 29. Identifying the PKA phosphorylation site on CaV1.4.   
(A) Sequence alignment of the core region of ICDI modules (identified by alanine scanning 
in previous studies89)  from CaV1.2, 1.3 and 1.4, with consensus symbols labelled 
underneath. Potential phosphorylation sites (STY) were colored green. The arrow indicates 
S1883. (B) pkaPS scores of potential phosphorylation sites in ICDI1.4. The corresponding 
sequence is displayed at the bottom on the x-axis in panel D, S1883 (green) has the highest 
score. (C) Dissociation constants (Kd_+PKAc) measured by FRET two-hybrid assays between 
Venus-IQ-A1.3 peptide and cereulan-ICDI1.4 peptides in the presence of overexpressed 
PKAc (Figure 31B, right). Every three contiguous residues within ICDI1.4 (corresponding 
to the bottom sequence in D) were systematically substituted by alanines89. The green 
dashed line marks the dissociation constant between Venus-IQ-A1.3 peptide and wild-type 
cereulan-ICDI1.4 peptides without overexpressing PKAc. The gray dashed line marks the 
dissociation constant between Venus-IQ-A1.3 and wild-type cereulan-ICDI1.4 peptides with 
overexpression of PKAc. With SAD1883AAA mutations (green), overexpressing PKAc 
fails to increase the dissociation constant of the two peptides (compare to D, green bar) 
indicating that S1883 is likely the PKA phosphorylation site. (D) Dissociation constants 
(Kd_-PKAc) measured by FRET two-hybrid assays between Venus-IQ-A1.3 and cereulan-
ICDI1.4 peptides without overexpressed PKAc (Figure 31B, left). The green and gray 
dashed lines are the same as in C. The corresponding ICDI1.4 sequence is labeled under the 
x-axis. The core region89 for IQ interaction is marked by the bar below the sequence.  
Mutations in three constructs (blue bars) reduced the dissociation constants of IQ/ICDI 































Figure 30. Additional information for mass spectroscopy experiments.   
(A) Coomassie blue stained SDS-PAGE gel loaded with purified double-histidine-labeled 
Cerulean-ICDI1.4 peptides (expected molecular weight: 40.8kD). The red arrow indicates 

































Figure 31. Identification of the PKA phosphorylation site within ICDI1.4. 
(A) The mass spectra of an ICDI1.4 peptide, showing phosphorylation at S1883. (B) High-
throughput FRET binding assays (C-E) between Venus-IQ-A1.3 and Cerulean-ICDI1.4 
demonstrating the modulation of binding due to PKAc overexpression. (C) Overexpression 
of PKAc reduced binding between IQ-A1.3 and wild-type ICDI1.4. (D) Overexpression of 
PKAc did not affect binding between IQ-A1.3 and ICDI1.4 harboring a S1883A mutation. 
(E) Overexpression of PKAc reduced binding between IQ-A1.3 and ICDI1.4 harboring a 
S1886A mutation. (F) Similar to wild-type CaV1.3S/1.4DCT channels (Figure 20F), 
CaV1.3S/1.4DCT channels containing the S1883A mutation had minimal CDI. (G) Unlike 
wild-type CaV1.3S/1.4DCT (Figure 20G), CaV1.3S/1.4DCT channels with the S1883A mutation 
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